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Chapter 4 
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Ligand Autoradiographical Comparison ofRo 25,6981 and CP-
101,606 in Normal Human Ageing and Dementia with Lewy Bodies 
4.1. Introduction 
The NMDA receptor is implicated in normal neuronal development (section 1.12), normal 
ageing (section 1.11) and neurological diseases (section 1.15, 1.16, 1.17) where changes in 
learning and memory may occur. Neurotoxicity may occur by over stimulation of the 
NMDA receptor due to excess excitatory amino acids, consequently raising intracellular 
calcium to damaging levels (Piggott et al., 1994). 
A number of NMDA receptor antagonists have been developed and used for the treatment 
of neurological diseases in patients. However, all of these drugs have been failed in clinical 
trials either because of intolerable side effects or lack of medical efficacy (Wang & Shuaib, 
2005). Understanding of the molecular structure of NMDA receptors has considerably 
increased, thus providing a new generation of NR2B subtype-selective antagonist 
congeners, based on the basic structure of Ifenprodil and Eliprodil. It is hoped that these 
NR2B subtype-specific antagonists will have superior therapeutic implications in disorders 
such as epilepsy, stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, 
neuropathic pain and psychiatric disorders such as anxiety and depression, but which lack 
the unwanted cognitive and motor side-effects (Nikam & Meltzer, 2002). NMDA receptor 
inhibition is used as a therapeutic strategy to prevent dramatic increases in extracellular 
glutamate levels resulting from prolonged over-activation of the receptors, which ultimately 
leads to neuron death. Neuronal apoptosis in this manner plays a major role in the 
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pathophysiology of PD, AD and DLB, and the NR2B subtype-selective antagonists CP-
101,606 and Ro 25,6981 compounds have therefore been chosen for this study. 
In PD, glutamatergic hyperactivity, secondary to the primary loss of dopamine, ts 
thought to play a role in the pathophysiology of the disease. Evidence suggests 
glutamatergic pathways involving the subthalamic nucleus, medial globus pallidus, 
substantia nigra pars reticula, basal ganglia and corticostriatal structures become overactive 
(DeLong, 1990; Calabresi et al., 1993; Tossman et al., 1986). NMDA receptors are 
widespread throughout these structures and thus may mediate many of the 
pathophysiological side-effects (Nikam & Meltzer, 2002). Recent studies provide evidence 
for the ability of NMDA receptor blockade to alleviate the symptoms of parkinsonism and 
augment the effectiveness of dopaminergic therapy. They have also demonstrated that in 
some paradigms NMDA antagonists can prevent or reverse the induction of levadopa-
related motor complications. 
Dementia with lewy bodies (DLB) is a primary, neurodegenerative dementia sharing 
clinical and pathological characteristics with both PD and AD (McKeith et al., 2003) (see 
1.16). The presenting feature for DLB patients is usually cognitive decline (Barber et al., 
2001) but there is often a relative preservation of short-term memory (McKeith, 2002). 
NMDA receptor antagonists maybe used as drug therapies to alleviate cognitive, 
psychiatric and motor disabilities, using the same rationale as for PD patients (Hallet & 
Standaert, 2004). Several studies have implicated the NR2B subunit to be an important 
target in the treatment of the dementia component of DLB. For example, a preliminary 
study by Piggott et al (1992) provided evidence that NMDA receptors with 
pharmacological properties indicative of the NRIINR2B subtype also decrease, in 
comparison to other subtypes, in aged humans. Clayton et al (2002) used animal models to 
demonstrate that reduced L TP and inferior cognitive performance correlated with a 
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decreased NR2B subunit expression with age. Over-expression of the forebrain NR2B 
subunit in transgenic mice (see 1.6.2) has been shown to have profound beneficial effects 
upon cognitive performance (Tang et al., 1999). In situ hybridisation experiments carried 
out by Bai et al (2004), showed a significant overall decrease in the mRNA expression of 
the NR2B subunit in the prefrontal cortex and caudate nucleus between young and old 
macaque monkeys. Magnusson & Cotman (1993) showed similar results using aged mice. 
Structure-activity relationship (SAR) studies of Ifenprodil analogues aimed at increasing 
potency and selectivity for NMDA receptors led to some second generation highly potent 
and selective NR2B antagonists. The work of Pfizer and Roche produced considerable 
advancement in this field, providing amongst others, the compounds CP-1 01,606 and Ro 
25,6981 respectively. CP-101,606 has been shown to be a potent neuroprotectant selective 
for forebrain neurons. Autoradiography indicated the CP-101,606 binding site is located in 
forebrain, most notably in hippocampus and the outer layers of cortex (Menniti et al., 
1997). The systemic administration ofCP-101,606 reduced parkinsonian symptoms in both 
haloperidol-treated rats and MPTP-lesioned non-human primates (Steece-Collier et al., 
2000). Its pharmacological profile has been widely reviewed (Nikam & Meltzer, 2002; 
Chazot et al., 2002; Chazot, 2000; Menniti et al., 1998; Chenard & Menniti, 1999). 
Fischer et al. (1997) studied the characteristics ofthe interaction between Ro 25,6981 and 
NMDA receptors in a variety of different tests in vitro. They demonstrated that Ro 25,6981 
is a highly selective, activity-dependant blocker ofNMDA receptors that contain the NR2B 
subunit, with potent neuroprotective effects in vitro. Mutel et al (1998) studied the in vitro 
binding properties of eH]Ro 25,6981 in rat brain using autoradiography. They detected a 
high density of binding sites in several layers of the cerebral cortex, in the hippocampus, 
dentate gyrus, caudate putamen, medium densities in the globus pallidus, thalamus, spinal 
cord dorsal horn and motomeurons, whereas the cerebellum, pons and medulla were poorly 
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labelled. Previous studies by Hawkins et al. (1999) have shown that Ro 25,6981 binds both 
NR11NR2B and NRIINR2AINR2B receptors with similar high affinities, suggesting that 
Ro 25,6981 is an NR2B-selective compound, irrespective whether complexed with other 
NR2 subunit types. Preliminary evidence from studies by Brimecombe et al. (1997) and 
Chazot et al. (2002) suggest that CP-10 I ,606 is NR2B selective and displays distinct 
pharmacological selectivity toRo 25,6981, in that it may be influenced by the presence of 
other NR2 subunit types within the receptor complex. 
Autoradiography of slide mounted post-mortem brain tissue provides a high resolution 
image of localised receptor binding, showing neuroanatomical detail between brain regions. 
In this study, autoradiographical techniques (Mutel et al., 1998) were carried out on a series 
of human control and diseased brain slices using the radiolabelled ligands eHJCP-101,606 
[(1 S,2S)-( 4-eH]hydroxyphenyl)-2-( 4-hydroxy-4-phenylpiperidino )-1-propanol], and 
[~Ro 25,6981 (R-(R * ,S*)-a-(4-eH]hydroxyphenyi)-P-methyl-4-(phenylmethyl)-1-
piperidine propanol]. The slices were taken from striatal and cortical sections of the brain. 
Spermidine, used to define specific binding of the radioligand (Hawkins et al. 1999), is an 
endogenous polyamine. Yoneda et al. (1991) showed that eH]spermidine binds specifically 
to brain membranes and that this binding is displaced totally by unlabelled spermine and 
spermidine (Nicolas & Carter, 1994). 
The aim of this study was to investigate the abundance and distribution of the NMDA 
NR2B subunit protein in DLB, PDD, DLBPDD, AD cases and respective controls, as well 
as any differences between the two NR2B radioligands used. The binding levels of Ro 
25,6981 would be predicted to be higher in general than those of CP-101,606 due to their 
suggested distinct NR2B subtype selectivities previously described. The aim was to show 
any binding site distribution patterns between control and diseased tissue, and also any age-
related changes there may be. The hypothesis was that the number of NR2B receptors 
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would decrease with age in control cases and the diseased cases would display lower NR2B 
subunit levels than the respective age-matched controls, and there would be a correlation 
with MMSE scores. 
4.2 Methods 
4.2.1 Cases used 
The 83 cases chosen for this study were at the level of the striatum (caudate nucleus and 
putamen) corresponding to coronal brain levels 9-15 using the Coronal Map of Brodmann 
Areas in the Human Brain (Perry 1993) (see figure 4.1). 29 of these were control cases 
showing no evidence of neurological or neuropathological disorder. 22 of these were DLB 
cases, 12 were DLBPDD cases, 9 were PDD cases, while 11 were AD cases each 
determined by pathological and clinical diagnosis (see Table 4.1). See also Table 4.2 for 
age-adjusted data sets for more accurate comparisons between the disease states. 
n= Age (years) PM Delay (hours) 
Total Females Males Ranee Mean SD Ran_ge Mean SD 
Control 29 17 12 62-91 77.79 7.69 8-96 39.57 23.48 
DLB 22 7 15 69-92 81.27 6.22 4-65 38.25 21.29 
DLBPDD 12 7 5 64-89 75.83 6.34 10-85 42.42 25.83 
PDD 9 2 7 65-86 75.56 7.35 7-77 36.75 20.65 
AD 11 7 4 78-91 84.18 4.29 10-82 30.73 20.84 
Table 4.1 Summary of the 83 cases chosen for the study. (SD =standard deviation of 
either age or PM delay values. PM delay= postmortem delay, that is, time between 
death and freezing of the tissue, to allow for post-mortem examination). 
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n= Age (years) 
Total Females Males Range Mean SD 
Control 26 15 11 67-91 79.39 6.36 
DLB 22 7 15 69-92 81.27 6.22 
DLBPDD 10 7 3 72-89 77.7 4.95 
POD 7 I 6 71-86 78 6.27 
AD 10 6 4 78-87 83.5 3.84 
Table 4.2 Summary of Cases with adjusted age-ranges and mean age values for 
comparison between control and disease state data sets. 
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Reproduced with kind permission of IAH Newcastle-upon ·Tyne. 
Figure 4.1: Coronal levels of striatum, 0.5 cm apart. AC =anterior commissure; Amyg = 
amygdala; Ant Nuc = anterior nucleus of thalamus; ant = anterior; Caud = caudate; Cerb 
Ped = cerebral peduncle; Chi = optic chiasma; cl = coronal level; Fx = fornix; GPe = 
external globus pallidus; Gpi = internal globus pallidus; Int Caps = internal capsule; Lat 
Vent Temp =temporal horn of lateral ventricle; MB = mammillary body; NA = nucleus 
accumbens; 0 Tb = olfactory tubercle; post = posterior; Putm = putamen 
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4.2.2 Tissue Isolation 
At post-mortem, brains were divided into two hemispheres. The right hemisphere was 
fixed in formalin for neuropathological assessment and the left hemisphere was sliced 
coronally into 1cm slices. The slices were sealed in airtight polythene, rapidly frozen in 
Arcton at -70°C and cooled further over liquid nitrogen. The frozen tissue slices were 
stored at -80°C. Prior to sectioning, tissue slices were warmed to 15°C and blocks 
containing the striatum were sub-dissected and mounted onto cryostat chucks with 8% 
carboxymethylcellulose. Coronal sections were cryostat sectioned at a thickness of 20 
microns using a Brights OTF cryostat, from a total of 83 dissected post-mortem brains 
obtained from the Newcastle-Upon-Tyne brain bank. Slides were prepared so that adjacent 
sections from each case were exposed to each of the two ligands used. For each case, 5 
replicates were cut to measure 3 total and 2 non-specific radioligand binding. Cryostat 
sections from snap-frozen human brain tissue were thaw mounted onto Vectabond-coated 
glass slides, air dried for 1-2 hours and stored at -80°C prior to receptor autoradiography. 
4.2.3 NMDA R2B receptor autoradiography 
The autoradiographical method used was that essentially described by Mutel et al. (1998), 
with some modifications made. Tissue sections were brought to room temperature (1 hour) 
and incubated in approximately 4 litres ofpre-incubation buffer (section 2.3.15) for 2 x 10 
minutes at room temperature. Each section was then incubated in a total volume of 1. 7ml 
buffer (medium size slides) or 1.4ml buffer (small size slides) containing 2 x Ko (lOnM) 
(Chazot et al. 2002) eHJCP-101,606 (specific activity = 29.6Ci/mmol, stored at -20°C) 
from Dr. Menniti (Pfizer, Groton, USA), or 2 x Ko (18.8nM) (Hawkins et al. 1999) eH]Ro 
25,6981 (specific activity = 25.6 Ci/mmol, stored at -20°C) from Dr. J. Kemp and 
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colleagues (Hoffmann LaRoche, Switzerland) for 90 minutes at 4°C, until equilibrium is 
reached. Non-specific binding was determined in the presence of 1 OmM unlabelled 
spermidine, an endogenous polyamine (as used by Chazot et al., 2002, rather than 10J.!M 
Ro 04, 5595, as by Mutel et al., 1998). The reaction was terminated by three washes in 
50mM Tris-HCL buffer pH 7.4 at 4°C (2 x 5 minutes and 1 x 15 minutes) using 
approximately 1 litre of buffer per wash. This was the optimal rinse time to produce the 
maximal relative specific binding. After the three buffer washes, slides were briefly dipped 
in ice-cold distilled water (2 seconds) and then dried in a stream of cold air for 1-2 hours. 
The sections were then transferred to X-ray cassettes, each including tritium 
autoradiographic microscales as calibration standards, and exposed against tritium-sensitive 
Hyperfilm for 6 weeks at 4°C. The exposed films were then developed in D-19 developer 
(Kodak) for 5 minutes at room temperature, fixed for 6 minutes in Unifix (Kodak), washed 
under running tap water for 20 minutes and dried. 
4.2.4 eH]Ro 25,6981 and eH]CP-101,606 
The radioligand concentrations used were greater than those stated by Mutel et al. (1998). 
Preliminary unpublished studies by M. Lake (2002) were carried out using a range of 
radioligand concentrations. The concentrations of the radioligands used were chosen so 
they were twice the affinity (K0 ) of their specific binding to ensure that each 
autoradiography run measured an acceptable number of receptor binding sites. The Ko of 
CP-101,606 is 5nM, and Ro 25,6981 is 9.4nM (Chazot et al., 2002). Therefore 10nM and 
18.8nM concentrations were used respectively. Before starting the experiment, the 
concentration of the incubation buffer containing the radio ligand was checked by taking a 
1 OOJ.!l aliquot into a scintillation vial with 2ml scintillation fluid (Packard Ultima Gold) and 
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measuring the dpm ( disintegrations per minute) value in a Packard tri-carb 1900CA 
scintillation counter. All 83 cases were analysed using the eH]Ro 25,6981 ligand and 25 
of these (7 controls, 12 DLB, 3 POD, I DLBPDD and 2 AD cases) were analysed using the 
eH]CP- I 01,606 ligand. The lower numbers of cases used were due to limited supply of 
eH]CP- I 01,606. 
4.2.5 Image Analysis 
The resulting brain images on the films were captured using a Dage 72 MTI CCD72S video 
camera and were quantitatively analysed by computer-assisted densitometry using 
Microcomputer Imaging Device (MCID Elite) version 7.0 software from Imaging research 
Inc., Ontario, Canada. The radioactive tritium standards were used to calculate a standard 
curve for each autoradiogram, which allowed the conversion from optical density values to 
units of concentration (femtomoles per mg of tissue protein), for each brain region 
analysed. The non-specific tissue sections were present on the same film as each of the 
corresponding total binding tissue sections for the same case. Specific binding was 
determined by subtracting mean non-specific binding from mean total binding. Brain 
structures were identified by reference to the Atlas of the Human Brain (Mai et al., 1997) 
and the mean and standard deviations for each brain structure in each section were 
calculated. Inter-assay variability was eliminated by using ligand concentrations that were 
at least twice the ligand affinity, using ligand from the same batch for each 
autoradiographical run, and by standardising each film using calibration microscales. 
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4.2.6 Statistical Analysis 
Statistical analysis performed involved correlation analysis and students unpaired t-test, 
indicated with the use of Microsoft Excel and GraphPad Prism to analyse individual 
regions of the brain. Statistical significance was set at the p<0.05 level for the correlation 
analysis, with a minimum n value of 5 or more, and at the p<0.05 level for the t-tests with a 
minimum n value of 4 or more for each data set. Graphs were constructed using GraphPad 
Prism version 4. One-way Anova tests were also performed using GraphPad Prism version 
4 to analyse statistical differences across data sets. Statistical significance was set at the 
p<0.05. 
4.3 The Mini Mental State Examination (MMSE) 
The Mini Mental State Examination (MMSE), validated and widely used since its creation 
in 1975, is an effective tool for assessing cognitive mental status. The MMSE is used to 
detect cognitive impairment and monitor response to treatment. It is an eleven question test 
covering five areas of cognitive function: orientation, attention/calculation, recall and 
language, and the ability to follow simple verbal and written commands. A score of 23 or 
below, from a possible 30, indicates cognitive impairment. The test is effective but does 
have limitations, for example, patients that are hearing and visually impaired or who have 
low English literacy, or with communication disorders may perform poorly even when 
cognitively intact (Folstein et al., 1975). The test provides a total score that places the 
individual on a scale of cognitive function. The values used in this study were those taken 
at the last assessment before death of the patient. 
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4.3.1 Mental Test Score (MTS) 
The mental test score is used in the psychological assessment of elderly patients, and 
attempts to quantify the patients' capabilities by assessing a variety of memory and 
cognition functions. The main areas of assessment are orientation, registration, attention 
and calculation, recall and language. A 37-item test is used, and is referred to as the Roth-
Hopkins test, taking its name from the creators ofthe test in 1953. An abbreviated 10-item 
Roth-Hopkins test is also widely used. This is a quicker and better tolerated test, useful in 
assessing mental impairment in patients in the community as well as in institutional care. A 
score of less than six in the 1 0-item test suggests dementia. A score in the range 0-30 in the 
37-item list suggests dementia. 
4.4 Unified Parkinson Disease Rating Scale (UPDRS) 
The UPDRS is a rating tool to follow the longitudinal course of Parkinson's Disease. It is 
made up of the 1) Mentation, Behaviour and Mood, 2) Activities of Daily Living (ADL) 
and 3) Motor sections. These are evaluated by interview. Some sections require multiple 
grades assigned to each extremity. A total of 199 points are possible, where 199 represents 
the worst (total) disability, and 0 represents no disability. The values used in this study 
were those taken at the last assessment before death of the patient. 
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Coronal PM 
Case ~ Age Sex Level As!onal State Delay 
(Years) 1 = Rapid Death {Hours) 
2 = Prolonged 
528 control 81 f 10 1 22 
980 control 85 m 10 1 23 
64.96 control 72 f 13 1 28 
975 control 70 m 10 1 50 
828 control 80 f 10 1 48 
I63.9 control 9I f 14 1 48 
879 control 85 f 15+ 1 96 
814 control 86 f 15 I 50 
I22.94 control 72 f I2 I 32 
823 control 85 f 14 1 50 
208.95 control 85 m 14 2 10 
1010 control 84 m I4 1 76 
I44.94 control 86 f 13 2 38 
909 control 66 f 14 1 24 
843 control 76 m 14 1 48 
986 control 78 m 10 l 42 
839 control 71 m 14 I 96 
926 control 78 m 13 2 11 
913 control 77 f 14 1 48 
97.97 control 71 m 14 2 31 
1014 control 67 m 15 l 10 
125.94 control 75 f 15 2 31 
922 control 84 f 15 I 43 
959 control 82 r 9-10 I 15 
288.99 control 62 r 11 2 
123.03 control 64 111 13 I 63 
907 control 81 f 14 I 51 
71.92 control 75 f 10 I 16 
96.02 control 87 111 10 I 8 
Table 4.3 Details of Control Cases used in the study (n = 29). 
In all tables ( 4.3 - 4. 7) all cases were labelled with eH]Ro 25,6981, only those in red were 
labelled with eH]CP-101,606 due to limited ligand availability. 
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Coronal PM 
Case :!:m£ ~ Sex Level Agonal State Delay 
(Years) I = Rapid Death (Hours) 
2 = Prolonged 
47.98 DLB 70 m I2 I 58 
205.95 DLB 85 f IO I I8 
60.98 DLB 77 f I5 I 48 
I92.96 DLB 79 m I4 I 16 
3.98 DLB 87 f I5 I 13 
110.96 DLB 84 m 11 I 51 
I9.98 DLB 79 m I4 I 26 
2.0I DLB 87 m 8 I 4 
96.93 DLB 75 m I4 I 52 
I25.97 DLB 86 m 13 I 60 
146.97 DLB 84 f 11 I 48 
113.03 DLB 77 m 10 I 
155.03 DLB 79 Ill 11 I 
7.03 DLB 88 f 11 I 
103.03 DLB 7] f 12 I 
80.01 DLB 9? m 10 I 
25.01 DLB 81 Ill 11 I 
295.99 DLB 89 Ill 10 I 65 
111.03 DLB 81 Ill 11 I 
4.03 DLB 69 f 14 I 
74.01 DLB 87 Ill 10 I 
22.04 DLB 79 Ill 12 I 
Table 4.4 Details of Dementia with Lewy Bodies (DLB) Cases used in the study 
(n = 22). 
Coronal PM 
Case Ivn£ ~ Sex Level Agonal State Delay 
(Years) I = Rapid Death (Hours) 
2 = Prolonged 
99I PDD 86 m 13 I 48 
711 PDD 72 m I4 I 7 
I030 PDD 84 m 11 I 77 
578 PDD 71 f I2 I 36 
338.9 PDD 65 f I2 I 24 
183.9I PDD 77 m 10 1 36 
65.98 PDD 7] m 8 I 24 
80.02 POD 69 m 12 I 
109.91 PDD 83 m 12 I 42 
Table 4.5 Details of Parkinson's Disease with Dementia (PDD) Cases used in the 
study (n = 9). 
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Coronal PM 
Case ~ Age Sex Level Agonal State Delay 
(Years) 1 = Rapid Death (Hours) 
2 = Prolonged 
131.96 DLBPDD 17 f 14 1 23 
19.95 DLBPDD 72 f 12 1 10 
171.96 DLBPDD 72 f 8 1 24 
26.98 DLBPDD 69 m 15 1 11 
124.96 DLBPDD 17 m 11 I 60 
123.97 DLBPDD 76 f 11 1 24 
136.98 DLBPDD 17 m 11 I 33 
75.97 DLBPDD 82 f 14 I 75 
59.96 DLBPDD 89 f 10 1 64 
153.96 DLBPDD 79 f 10 1 64 
17.99 DLBPDD 76 m 14 1 85 
151.98 DLBPDD 64 m 15 I 36 
Table 4.6 Details of Dementia with Lewy Bodies+ PDD symptoms (DLBPDD) Cases 
used in the study (n = 12). 
Coronal PM 
Case ~ ~ Sex Level Agonal State Delay 
(Years) 1 = Rapid Death (Hours) 
2 = Prolonged 
136.95 AD 87 f 14 I 10 
194.97 AD 87 m 14 1 15 
131.98 AD 83 f 10 I 10 
35.97 AD 87 f 11 I 35 
172.95 AD 87 f 12 1 28 
116.96 AD 78 f 10 I 41 
291.99 AD 78 m 9 1 20 
279.99 AD 91 f 12 I 17 
10.97 AD 84 m 14 I 40 
183.96 AD 85 m 11 I 40 
19.96 AD 79 f 11 I 82 
Table 4. 7 Details of the Alzheimer's Disease (AD) Cases used in the study 
(n = 11). 
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Figure 4.1(a) Agonal State score against [3H]Ro 25,6981 specific binding 
(fmollmg) for Control cases, showing (A) Putamen and (B) Insular Cortex. 
1 =rapid death, 2=prolonged death. 
All DLB, PDD, DLBPDD and AD cases had agonal state scores of 1, indicating a 
rapid death. Therefore there was no comparison to be made between these cases. 
However, in the control data set, there was a mix of agonal state scores 1 and 2. 
Figure 4.1(a) shows a comparison ofthe [3H]Ro 25,6981 binding densities in two 
representative brain areas (putamen and insular cortex) for both agonal state 
scores. There was no significant difference seen in the binding densities between 
agonal state scores and this would suggest that agonal state is not a significant 
factor in determining density of NR2B-containing NMDA receptors in post-
mortem tissue. Rapid or prolonged death does not appear to affect the receptor 
population in this way. 
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-'Cl N 
Case ~ Age Sex MMSE UPDRS DeJ!ression Delusions Dementia Vis Hall 
(Years) 
47.98 DLB 70 m 9 12 1 2 2 
205.95 DLB 85 f 0 0 0 2 2 2 
60.98 DLB 77 f 16 12 0 1 1 1 
192.96 DLB 79 m 16 1 0 1 2 
3.98 DLB 87 f 19 6 0 0 1 0 
110.96 DLB 84 m 18 0 0 1 1 2 
19.98 DLB 79 m 25 13 0 0 1 1 
2.01 DLB 87 m 10 0 0 1 2 1 
96.93 DLB 75 m 15 10 0 1 1 1 
125.97 DLB 86 m 20 0 0 1 0 
146.97 DLB 84 f 20 0 0 0 1 0 
113.03 DLB 77 m 
155.03 DLB 79 m 
7.03 DLB 88 f 
103.03 DLB 73 f 
80.01 DLB 92 m 
25.01 DLB 81 m 
295.99 DLB 89 m 
111.03 DLB 81 m 
4.03 DLB 69 f 
74.01 DLB 87 m 
22.04 DLB 79 m 
Table 4.8 Clinical Details of DLB cases. 
MMSE =Mini mental state examination score. UPDRS =Unified Parkinson disease rating scale 
Depression: 0 = none, 1 = mild, 2 = severe. Delusions: 0 = none, 1 = mild, 2 = severe. Dementia: 0 = none, 1 = mild, 2 = severe. 
Vis Hall (visual hallucinations): 0 =none, 1 =mild, 2 =severe. 
-1.0 
w 
Case !m£ Age Sex MMSE UPDRS De(!ression Delusions Dementia Vis Hall 
(Years) 
991 POD 86 m 5 I 0 
7II POD 72 m I 
1030 POD 84 m I 1 
578 POD 7I f 5 I 0 
338.9 POD 65 f 2 1 
I83.91 POD 77 m 1 1 1 
65.98 POD 73 m 21 10 0 I 1 
80.02 POD 69 m 
109.91 POD 83 m 2 1 
Case !m£ Age Sex MMSE UPDRS De(!ression Delusions Dementia Vis Hall 
(Years) 
131.96 DLBPDD 77 f 3 9 2 1 2 2 
I9.95 DLBPDD 72 f 12 15 0 0 2 2 
171.96 DLBPDD 72 f 0 10 1 2 2 2 
26.98 DLBPDD 69 m 10 7 0 2 2 2 
124.96 DLBPDD 77 m 15 9 0 2 1 2 
123.97 DLBPDD 76 f 11 IO 0 1 2 2 
136.98 DLBPDD 77 m 12 1 I 0 
75.97 DLBPDD 82 f I I2 1 2 2 2 
59.96 DLBPDD 89 f I 8 1 I 2 2 
I53.96 DLBPDD 79 f 22 11 0 0 I 2 
I7.99 DLBPDD 76 m 21 IO 1 0 I 0 
I51.98 DLBPDD 64 m I4 19 0 1 0 
Table 4.9 (above) Clinical Details ofPDD cases. Table 4.10 (below) Clinical Details ofDLBPDD cases 
MMSE = Mini mental state examination score. UPDRS = Unified Parkinson disease rating scale 
MTS 
25 
29 
33 
20 
24 
11 
I 
Depression: 0 = none, 1 = mild, 2 = severe. Delusions: 0 = none, 1 = mild, 2 = severe. Dementia: 0 = none, 1 = mild, 2 = severe. 
Vis Hall (visual hallucinations): 0 =none, 1 =mild, 2 =severe. 
...... 
~ 
Case ill!!: Age Sex MMSE UPDRS DeJ!ression Delusions Dementia Vis Hall ! 
(Years) 
136.95 AD f 87 1 14 0 2 1 2 
194.97 AD m 87 0 
131.98 AD f 83 0 1 2 
35.97 AD f 87 5 4 0 2 1 2 
172.95 AD f 87 14 7 2 0 1 0 
116.96 AD f 78 6 2 2 0 1 0 
291.99 AD m 78 18 2 0 1 1 1 
279.99 AD f 9I 
I0.97 AD m 84 I6 5 0 2 I 0 
I83.96 AD m 85 I4 6 0 2 0 2 
I9.96 AD f 79 0 2 2 0 I 0 
Table 4.11 Clinical Details of AD cases. 
MMSE = Mini mental state examination score. UPDRS = Unified Parkinson disease rating scale 
Depression: 0 = none, 1 = mild, 2 = severe. Delusions: 0 = none, 1 = mild, 2 = severe. Dementia: 0 = none, 1 = mild, 2 = severe. 
Vis Hall (visual hallucinations): 0 =none, 1 =mild, 2 =severe . 
4.5 Results 
4.5.1 Results (Figure 4.2 to Figure 4.8) 
The first section of the results (Figure 4.2- 4.8) shows a qualitative analysis ofthe binding 
data, which is followed in the second section by quantitative analysis of the binding levels 
in each tissue. Figure 4.2 is given as an example showing the typical pattern of radioligand 
binding seen in many of the brain sections analysed, in this instance eH]CP-1 01,606 has 
been used. The darker areas indicate those which have been labelled by the radioligands, 
the greater the intensity, the higher the binding density in that tissue. The section is cut at 
coronal level 11, see figure 4.1, where the striatal caudate and putamen areas are beginning 
to separate and the nucleus accumbens is clearly visible. The globus pallidus is not yet 
apparent at this level. The claustrum can be seen along the outer curved edge of the 
putamen, and can be used as a good indicator for the orientation of the section. The insular 
cortex is also well labelled, and has been divided into two, the outer insular cortex has been 
analysed as a separate region since many sections showed an interesting clearly visible 
higher binding level than that seen in the insular cortex as a whole. The cingulate cortex is 
also well labelled and is located on the same side of the striatum as the caudate. 
Figures 4.3 to 4.8 show digital photographic examples of both eH]Ro 25,6981 (left hand 
side) and eH]CP-101,606 (right hand side) binding in control, DLB, PDD, and AD cases 
respectively. In each case figures A and B show the total binding of the radioligand, and the 
figures C and D show the non-specific binding, defined by 1 OmM spermidine. As described 
in section 4.2.5, the specific value is calculated by subtracting mean non-specific binding 
from mean total binding. In each of the examples shown, ligand binding was seen in the 
caudate, putamen, nucleus accumbens, insular, outer insular and cingulate cortex regions 
195 
and the claustrum. Binding was also observed in the globus pallidus when present in the 
tissue. The following table is a summary of the images shown. 
Coronal 
Figure Group Case no. level Age Sex 
4.3 Control 96.02 10 87 m 
4.4 Control 959 9 to 10 82 f 
4.5 DLB 80.01 10 92 m 
4.6 DLB 146.97 11 84 f 
4.7 PDD 80.02 12 69 m 
4.8 AD 183.96 11 85 m 
Table 4.12 Summary of example cases showing digitally photographed images from the 
autoradiographic films. 
4.5.2 Results (Figure 4.9 (A-C) to Figure 4.19). Refer to legends below each figure. 
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Cingulate cortex 
Caudate 
Putamen 
Claustrum 
Insular 
·~ortex 
..-------- Outer Insular 
Cortex 
Nucleus 
Accumbens 
0 10 mm 
Figure 4.2 Representative Example of a Human brain section (84 
years, female). NR1/NR2B receptors labelled by [3H]CP-101,606. 
Specific binding defmed using 1 OmM spermidine. 
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PIDRo 25, 6981 PIDCP-101,606 
A B 
Caudate Caudate 
394 fmoJ/mg 92 fmollmg 
Total 
c D 
Caudate Caudate 0 lOmm 
157 fmollmg 27 fmoJ/mg L_____j 
Non-specific 
Figure 4.3 (A-D) Autoradiography of Control Human Brain Slices (87 
years, male). (A) Total binding [3H]Ro 25,6981, (B) Total binding 
[3H]CP-101,606, (C) Non-specific binding [3H]Ro 25,6981 and (D) Non-
specific binding [3H)CP-101,606. Specific binding defmed using 10mM 
spermidine. 
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PIDRo 25,6981 PIDCP-101,606 
A B 
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c D 
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L__j 
Non-specific 
Figure 4.4 (A-D) Autoradiography of Control Human Brain Slices (82 years, 
female). (A) Total binding [3H]Ro 25,6981, (B) Total binding [3H]CP-
101,606, (C) Non-specific binding [3H]Ro 25,6981 and (D) Non-specific 
binding [3H]CP-101,606. Specific binding defmed using 10mM spermidine. 
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Figure 4.5 (A-D) Autoradiography of DLB Human Brain Slices (92 
years, male). (A) Total binding [3H]Ro 25,6981, (B) Total binding 
[3H]CP-101,606, (C) Non-specific binding [3H]Ro 25,6981 and (D) 
Non-specific binding [3H]CP-101,606. Specific binding defined using 
1 OmM spermidine. 
l___l 
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Figure 4.6 (A-D) Autoradiography of DLB Human Brain Slices (84 
years, female). (A) Total binding [3H]Ro 25,6981, (B) Total binding 
[3H]CP-101,606, (C) Non-specific binding [3H]Ro 25,6981 and (D) Non-
specific binding [3H]CP-101,606. Specific binding defined using 10mM 
spermidine. 
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PIDRo 25,6981 PIDCP-101,606 
A B 
Total 
c D 
0 lOmm 
L___l 
Non-specific 
Figure 4.7 (A-D) Autoradiography ofPDD Human Brain Slices (69 years, male). 
(A) Total binding [3H]Ro 25,6981, (B) Total binding [3H]CP-101,606, (C) Non-
specific binding [3H)Ro 25,6981 and (D) Non-specific binding [3H]CP-101,606. 
Specific binding defined using 10mM spermidine. 
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PIDRo 25,6981 PIDCP-101,606 
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Figure 4.8 (A-D) Autoradiography of AD Human Brain Slices (85 years, 
male). (A) Total binding [3H]Ro 25,6981, (B) Total binding [3H]CP-101,606, 
(C) Non-specific binding [3H]Ro 25,6981 and (D) Non-specific binding 
[3H]CP-101,606. Specific binding defined using 10mM spermidine. 
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Fieure 4.9 (A). Graph showing the significant differences in specific binding 
(fmollmg) densities (mean± SEM for n determinations) between [3H]Ro 25,6981 and 
eH]CP-101,606 in pooled male and female Control cases. 
Brain tissue samples from the 29 control cases described in section 4.2.1 and summarised 
in table 4.1 were assayed for radio labelled Ro 25,6981 and CP-1 0 l ,606 binding by 
autoradiography. As shown in figure 4.9(A), there were significantly higher levels of 
binding with eH]Ro 25,6981 than with eH]CP-101,606 (p~O.OOOI, two-tailed 
distribution, unpaired t-test) in all 8 brain regions defined. Binding of both radioligands 
showed differences between the regions analysed, with binding levels in the claustrum, 
external globus pallidus and internal globus pallidus consistently lower than all other 
regions for eH]Ro 25,6981 and eH]CP-101,606. These data were further analysed for 
gender differences, see figure 4.9(B,C). Due to low n values in the eH]CP-101,606 male 
and female cohorts, external and internal globus pallidus data were excluded. A similar 
pattern of binding was seen for male and female cases to that of the total cases, showing 
significantly more binding of eH]Ro 25,6981 than eHJCP-101,606 (females p~0.0003, 
males p~0.004, two-tailed distribution, unpaired t-test) in all 6 regions defined. There was 
no evidence for gender bias. Male cases for eH]CP-101,606 showed similar absolute 
binding levels to female cases although were not statistically valid due to low n values. 
All cases were statistically valid where (n ~5). 
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Figure 4.9 (B,C) Graph showing the significant differences in specific binding 
(fmollmg) densities (mean ± SEM for n determinations) between eH]Ro 25,6981 
and eH]CP-101,606 in (B) female and (C) male Control cases. 
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Figure 4.10 (A). Graph showing the significant differences in specific binding 
(fmollmg) densities (mean± SEM for n determinations) between eH]Ro 25,6981 
and eHJCP-101,606 in pooled male and female DLB cases. 
Brain tissue samples from the 22 DLB cases described in section 4.2.1 and summarised 
in table 4.1 were assayed for radio labelled Ro 25,6981 and CP-10 1,606 binding by 
autoradiography. As shown in figure 4.10(A), there were significantly higher levels of 
binding with eHJRo 25,6981 than with eHJCP-101,606 (p~0 .0001 , two-tailed 
distribution, unpaired t-test) in all 7 brain regions defmed. Binding of both radioligands 
showed differences between the regions analysed, with binding levels in the claustrum 
consistently lower than all other regions for eHJRo 25,6981 and eHJCP-101,606. These 
data were further analysed for gender differences, see figure 4.1 O(B,C). A similar 
pattern of binding was seen for male and female cases to that of the total cases, showing 
significantly more binding of eHJRo 25,6981 than eHJCP-101 ,606 (females p~0.02, 
males p~O.OO 1, two-tailed distribution, unpaired t-test) in all 7 regions defmed. There 
was no evidence for gender bias. Female cases for eHJCP-10 I ,606 showed similar 
absolute binding levels to male cases although were not statistically valid due to low n 
values. All cases were statistically valid where (n ~5) . 
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Figure 4.10 (B,C) Graph showing the significant differences in specific binding 
(fmollmg) densities (mean± SEM for n determinations) between eHJRo 
25,6981 and eHJCP-101,606 in (B) female and (C) male DLB cases. 
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Figure 4.11. Graph showing the significant differences in specific binding 
(fmollmg) densities (mean± SEM for n determinations) between eHJRo 25,6981 
and eHJCP-101,606 in pooled male and female PDD cases. 
Brain tissue samples from the 9 PDD cases described in section 4.2.1 and summarised 
in table 4.1 were assayed for radio labelled Ro 25,6981 and CP-10 1,606 binding by 
autoradiography. As shown in figure 4.11 , there were significantly higher levels of 
binding with eH]Ro 25,6981 than with eH]CP-101 ,606 (p~0.03 , two-tailed 
distribution, unpaired t-test) in all 6 brain regions defined. Binding of both 
radioligands showed differences between the regions analysed, with binding levels in 
the caudate and claustrum consistently lower than all other regions for eHJRo 
25,6981 and eH]CP-1 01 ,606. A similar pattern of binding levels was observed across 
the range of brain regions for eH]Ro 25,6981 and eH]CP-101 ,606. Due to low n 
values in the CP-1 01 ,606 male and female cohorts these data were not further 
analysed for gender differences as results would not be statistically relevant. All cases 
were statistically valid where (n ~5) . 
208 
n = 
250 
l 200 
~ 
11 
11 11 8 
11 
bO 150 j lOO 10 
i 50 
0 
PHJ Ro25.@81 
7 
2 2 
2 2 2 
• 
2 
I 
PHJ CP-101,~ 
2 
- Grudate 
-Namen 
- Clalmun 
- IrBllar O:r1ex 
c:::J ~ O:r1ex 
Q1er Insular Grex 
c:::J Accunbens 
Figure 4.12. Graph showing the significant differences in specific binding (fmol/mg) 
densities (mean ± SEM for n determinations) between eH]Ro 25,6981 and eH]CP-
101,606 in pooled male and female AD cases. 
Brain tissue samples from the 11 AD cases described in section 4.2.1 and summarised in 
table 4.1 were assayed for radiolabelled Ro 25,6981 and CP-10 1,606 binding by 
autoradiography. As shown in figure 4.12, there were significantly higher levels of 
binding with eH]Ro 25,6981 than with eH]CP-1 01,606 (p:s;0.04, two-tailed distribution, 
unpaired t-test) in all brain regions defined except in the claustrum where p=0.21 showing 
no significance (indicated by • ). However, the small n value (n=2) may negate this result. 
Binding of both radioligands showed differences between the regions analysed, with 
binding levels in the claustrum consistently lower than all other regions for eH]Ro 
25,6981 and eH]CP-1 01,606. A similar pattern of binding levels was observed across the 
range of brain regions for eH]Ro 25,6981 and eHJCP-101 ,606. Due to low n values in 
the CP-1 01 ,606 male and female cohorts these data were not further analysed for gender 
differences as results would not be statistically relevant. All cases were statistically valid 
where (n ~5) . 
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Figure 4.12(a) Graphs showing [3H]Ro 25,6981 specific binding (fmollmg) 
densities (mean± SEM for n determinations) for DLB, PDD and AD cases 
for (A) Caudate (B) Putamen (C) Claustrum (D) Insular Cortex (E) 
Cingulate Cortex (F) Outer Insular Cortex and (G) Accumbens. 
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Figure 4.12(a) shows there are no significant differences in the binding 
densities of [3H]Ro 25,6981 in all of the brain areas analysed when 
comparing between the disease states. On first glance there appears to be a 
general trend for the binding to be lower in PDD cases in all the regions, 
although this is not statistically significant. Statistical analysis was performed 
using a one-way anova test, indicated with the use of GraphPad Prism 
(version 4) to analyse between disease states in individual regions of the 
brain. Statistical significance was set at p<0.05 level for the one-way anova 
analysis. 
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Figure 4.12(b) Graphs showing [3H]CP-101,606 specific binding (fmollmg) 
densities (mean± SEM for n determinations) for DLB, PDD and AD cases 
for (A) Caudate (B) Putamen (C) Claustrum (D) Insular Cortex (E) 
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Figure 4.12(b) shows that when comparing between the disease states, there 
are no significant differences in the binding densities of [lH]CP-101 ,606 in 
all of the brain areas analysed, with the exception of the cingulate cortex 
where the AD cases show significantly higher binding than the DLB and PDD 
cases (p=O.OO). There would appear to be a general trend for the binding to be 
higher in AD cases in all the regions, although this was not statistically 
significant due to the low n numbers. Statistical analysis was initially 
performed using a one-way anova test (GraphPad Prism) and then a students 
unpaired t-test, (Microsoft Excel) to analyse individual regions of the brain. 
Statistical significance was set at p<0.05 level for anova and t-test analysis. 
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-.J::o.. 
(A) Male and Female 
Caudate Putamen Claustnun Insular ex Cingulate ex Out ins ex ExtGP lntGP Aeeumbs 
Control 38 33 23 35 45 41 8 12 
DLB 35 31 23 35 34 42 33 
PDD 41 43 37 42 44 48 
AD 57 53 49 59 63 55 
---
L__ 61 
(B) Female 
Caudate Putamen Claustnun Insular ex Cingulate ex Out ins ex Aeeumbs Ron= CPn= 
Control 37 31 24 37 45 42 6-17 3-5 
DLB 35 31 30 35 35 50 43 3-7 2-4 
(C) Male 
Caudate Putamen Claustnun Insular ex Cingulate ex Out ins ex Aeeumbs Ron= CPn= 
Control 40 38 20 34 47 45 6-12 1-2 
DLB 35 31 19 35 33 40 28 7-15 5-8 
Table 4.13 (A)-(C) 
Percentage Specific Binding of eH]CP-101,606 relative to eH]Ro 25,6981 in (A) Male and Female cases, 
(B) Female cases and (C) Male cases. 
Ron= CPn= I 
12-29 2-7 
I 
11-22 8-12 
5-9 2-3 
7-11 2 
I 
4.5.2 Results (Table 4.13 (A-C) 
Table 4.13 (A) shows the percentage specific binding of eH]CP-1 01,606 relative to eH]Ro 
25,6981 in each of the brain regions analysed for the pooled male and female data in 
control and disease cases. The main observation from these results is that in all control, 
DLB and POD cases and for all brain regions, the percentage binding levels were all less 
than 50%. Percentages in the control cases ranged from 8% (external globus pallidus) to 
45% ( cingulate cortex). Percentages in DLB cases ranged from 23% (claustrum) to 42% 
(outer insular cortex). Percentages in POD cases ranged from 37% (claustrum) to 48% 
(outer insular cortex). The AD cases however showed that eH]CP-101,606 binding levels 
were proportionately higher than controls, DLB and POD cases since relative percentages 
for each region were all greater than 50%, with the exception of the claustrum with 49%. 
Percentages ranged from 53% (putamen) to 63% ( cingulate cortex). 
Tables 4.13 (B) and (C) show the same data but divided into female and male cases to see if 
there is any evidence for gender bias in the relative percentages of eH]CP-1 01,606 binding 
to eH]Ro 25,6981. Only control and DLB data has been analysed due to low n numbers in 
the POD and AD cohorts. In the control cases there was no clear trend, percentages were 
higher in the female data set in the claustrum and insular cortex, but were higher in the 
male data set in the caudate, putamen, cingulate cortex and outer insular cortex. In the DLB 
cases, all relative percentages were either identical in both male and female data sets 
(caudate, putamen and insular cortex) or there was a bias towards female percentages being 
higher than the male (claustrum, cingulate cortex, outer insular cortex and accumbens). 
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Fieure 4.13 (A) Graph showing (mean± SEM for n determinations) densities of 
[3H]Ro 25,6981 specific binding (fmollmg) in control and DLB pooled male and 
female cases in various brain regions. 
Brain tissue samples from the 29 control cases and 22 DLB cases described in table 4.1 
were assayed for radiolabelled Ro 25,6981 binding by autoradiography. Results oftheir 
analysis as previously shown (see graph 4.9 (A-C) and graph 4.10 (A-C)) were 
combined to assess the potential differences between control and disease state binding 
levels (finol/mg) in the brain regions specified. As shown in figure 4.13(A), there were 
no significant differences in the levels of eHJRo 25,6981 binding between control and 
DLB cases (JV-0.12, two-tailed distribution, unpaired t-test) in all 9 brain regions 
analysed. These data were further analysed for gender differences, see figure 4.13(B,C). 
A similar pattern of binding was seen across the brain regions for male and female 
graphs both separately and combined, showing no significant differences between 
control and DLB cases (females JY-0.47 with the exception of the cingulate cortex where 
p=O.Ol (indicated by •), and males p;:::O.l, two-tailed distribution, unpaired t-test) in all 9 
regions defined. There was no evidence for gender bias except in the cingulate cortex. 
The claustrum, external and internal globus pallidus binding levels were consistently 
lower comoared to all other rel!ions. All values were statisticallY valid where n;:::5. 
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Figure 4.13 (B,C) Graphs showing (mean± SEM for n determinations) 
densities of eHJRo 25,6981 specific binding (fmollmg) in control and DLB 
in (B) female and (C) male cases in various brain re2ions. 
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Figure 4.14 Graph showing (mean± SEM for n determinations) densities of 
eH]CP-101,606 specific binding (fmol/mg) in control and DLB pooled male 
and female cases in various brain regions. 
Brain tissue samples from the 7 control cases and 12 DLB cases described in table 
4.1 were assayed for radio labelled CP-1 0 l ,606 binding by autoradiography. 
Results of their analysis as previously shown (see graph 4.9 (A-C) and graph 4.10 
(A-C)) were combined to assess the potential differences between control and 
disease state binding levels (frnoVmg) in the brain regions specified. As shown in 
figure 4.14, there were no significant differences in the levels of eH]CP-1 01,606 
binding between control and DLB cases (p;:::O.ll , two-tai led distribution, unpaired 
t-test) in all 6 brain regions analysed. Due to low n values in the CP-101 ,606 male 
and female cohorts these data were not further analysed for gender differences as 
results would not be statistically relevant. The claustrum binding levels were 
consistently lower compared to all other regions. All values were statistically valid 
where ~5 . 
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Figure 4.15 (A) Graph showing (mean± SEM for n determinations) 
densities of eH]Ro 25,6981 specific binding (fmol/mg) in control and PDD 
pooled male and female cases in various brain regions. 
Brain tissue samples from the 29 control cases and 9 PDD cases described in 
table 4.1 were assayed for radiolabelled Ro 25,6981 binding by autoradiography. 
Results of their analysis as previously shown (see graph 4.9 (A-C) and graph 
4.11) were combined to assess the potential differences between control and 
disease state binding levels (fmol/mg) in the brain regions specified. As shown 
in figure 4.15(A), there were no significant differences in the levels of eH]Ro 
25,6981 binding between control and PDD cases (IY-:0.08, two-tailed distribution, 
unpaired t-test) in all brain regions analysed except in the claustrum where 
p=0.04, showing significance (indicated by • ). The caudate and insular cortex 
appear to suggest a higher binding level in the controls compared to PDD cases, 
although the differences are not statistically significant (p=0.12 and p=0.08 
respectively). This may be due to the considerable difference in n numbers 
between the two groups. 
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Figure 4.15 (B) Graph showing (mean ± SEM for n determinations) densities of 
eHJRo 25,6981 specific binding (fmoVmg) in control and PDD male cases in 
various brain regions. 
These data were further analysed for gender differences, see figure 4.15(B). Due to 
low n values in the Ro 25,6981 PDD female cohort, these data were not further 
analysed for gender differences as results wou ld not be statistically relevant. A similar 
pattern of binding was seen across the brain regions for male and combined male and 
female graphs, showing no significant differences between control and PDD cases 
(male p~0.06, two-tailed distribution, unpaired t-test) in all 9 regions defined. There 
appears to be a trend for higher binding in the controls in the caudate, claustrum and 
insular cortex, although this is not statistically significant since p=0.23, p=O.ll and 
p=0.06 respectively. There was no evidence for gender bias. The claustrum, external 
and internal globus pallidus binding levels were consistently lower compared to all 
other regions. All values were statistically valid where ~5 . 
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Figure 4.16 Graph showing (mean± SEM for n determinations) densities of 
CHJCP-101,606 specific binding (fmol/mg) in control and PDD pooled male and 
female cases in various brain regions. 
Brain tissue samples from the 7 control cases and 3 PDD cases described in table 4.1 
were assayed for radio labelled CP-1 01,606 binding by autoradiography. Results of their 
analysis as previously shown (see graph 4.9 (A-C) and graph 4.11) were combined to 
assess the potential differences between control and disease state binding levels 
(fmoVmg) in the brain regions specified. As shown in figure 4.16, there were no 
significant differences in the levels of eHJCP-1 01 ,606 binding between control and 
PDD cases (p>0.1, two-tailed distribution, unpaired t-test) in all 6 brain regions 
analysed. Due to low n values in the CP-101 ,606 male and female cohorts these data 
were not further analysed for gender differences as resu lts would not be statistically 
relevant. The claustrum binding levels were consistently lower compared to all other 
regions. All values were statistically valid where n2:5. 
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Figure 4.17 (A) Graph showing (mean ± SEM for n determinations) densities 
of eH]Ro 25,6981 specific binding (fmollmg) in control and DLBPDD pooled 
male and female cases in various brain regions. 
Brain tissue samples from the 29 control cases and 12 DLBPDD cases described in 
table 4.1 were assayed for radiolabelled Ro 25,6981 binding by autoradiography. 
Results of their analysis as previously shown (see graph 4.9 (A-C), DLBPDD data 
not previously shown) were combined to assess the potential differences between 
control and disease state binding levels (fmollmg) in the brain regions specified. 
As shown in figure 4.17(A), there were no significant differences in the levels of 
eHJRo 25,6981 binding between control and DLBPDD cases (p>0.24, two-tailed 
distribution, unpaired t-test) in all 8 brain regions analysed. These data were 
further analysed for gender differences, see figure 4.17(B,C). A similar pattern of 
binding was seen across the brain regions for male and female graphs both 
separately and combined, showing no significant differences between control and 
DLB cases (females (20.08, males p~0.06 with the exception of the caudate where 
p=O.Ol, and the Insular Cortex where p=0.02, two-tailed distribution, unpaired t-
test, indicated by • ) in all 9 regions defined. The claustrum, external and internal 
globus pallidus binding levels were consistently lower compared to all other 
regions. All values were statistically valid where ~5. 
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Figure 4.17 (B,C) Graph showing (mean± SEM for n determinations) densities 
of eH]Ro 25,6981 specific binding (fmollmg) in control and DLBPDD (B) 
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Figure 4.18 (A) Graph showing (mean± SEM for n determinations) densities of 
eHJRo 25,6981 specific binding (fmollmg) in control and AD pooled male and 
female cases in various brain regions. 
Brain tissue samples from the 29 control cases and 11 AD cases described in table 4.1 
were assayed for radiolabelled Ro 25,6981 binding by autoradiography. Results of 
their analysis as previously shown (see graph 4.9 (A-C) and graph 4.12) were 
combined to assess the potential differences between control and disease state binding 
levels (fmol/mg) in the brain regions specified. As shown in figure 4.18(A), there 
were no significant differences in the levels of eH]Ro 25,6981 binding between 
control and AD cases (p>O.l , two-tailed distribution, unpaired t-test) in all brain 
regions analysed. 
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Figure 4.18 (B) Graph showing (mean± SEM for n determinations) densities of 
eHJRo 25,6981 specific binding (fmoUmg) in control and AD female cases in 
various brain regions. 
These data were further analysed for gender differences, see figure 4.18(B). Due to 
low n values in the Ro 25,6981 AD male cohort, these data were not further 
analysed for gender differences as results would not be statistically relevant. A 
similar pattern of binding was seen across the brain regions for female and 
combined male and female graphs, showing no significant differences between 
control and AD cases (male p>O.l , two-tailed distribution, unpaired t-test) in all 9 
regions defined. There was no evidence for gender bias. The claustrum, external and 
internal globus pallidus binding levels were consistently lower compared to all other 
regions. All values were statistically valid where ~5. 
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Figure 4.19 Graph showing (mean± SEM for n determinations) densities of 
eH]CP-101,606 specific binding (fmollmg) in control and AD pooled male and 
female cases in various brain regions. 
Brain tissue samples from the 7 control cases and 2 AD cases described in table 4.1 
were assayed for radiolabelled CP-101 ,606 binding by autoradiography. Results of 
their analysis as previously shown (see graph 4.9 (A-C) and graph 4.12) were 
combined to assess the potential differences between control and disease state binding 
levels (fmoVmg) in the brain regions specified. As shown in figure 4.19, there were no 
significant differences in the levels of eHJCP-l 0 l ,606 binding between control and 
AD cases (p~0.09, two-tailed distribution, unpaired t-test) in all 6 brain regions 
analysed except in the cingulate cortex where p=0.004, showing significance, 
(indicated by •). This may be due to the low n values in the AD cases, since the graph 
would appear to show significance between AD and control values. Due to low n 
values in the CP-1 0 I ,606 male and female cohorts these data were not further 
analysed for gender differences as results would not be statistically relevant. The 
claustrum binding levels were consistently lower compared to all other regions. All 
values were statistically valid where n2:::5. 
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4.5.3. Results (Figure 4.20 CA-H) to Figure 4.25 CA-G)) 
The same data as previously described (see graphs 4.9 (A-C) to graph 4.19) were further 
analysed to show specific binding levels of both [3H]Ro 25,6981 and eH]CP-101,606 in 
various brain regions, correlating fmol/mg binding with age at death of the subject (in years) 
for each case, and in each brain region defined. Estimated linear regression lines of best fit 
were produced using GraphPad Prism and are represented on each graph, indicating any 
age-dependant changes in binding levels in each tissue. The significance of the regression 
was determined from the generated p value, where ~0.05 was considered to show a 
significant linear relationship between age and binding level. Due to limited availability of 
the eH]CP-101,606 ligand a smaller number of cases were analysed, resulting in low n 
numbers for some of the tissues. In these cases a linear regression line was not shown as it 
would not have been appropriate where n = <3. The generated correlation coefficient or r 
value shows how well the data fits to the regression line, where r = 1 shows strong 
correlation and r = 0 shows little or none. 
Figure 4.20 (A-H) shows the specific binding levels in male and female control cases for 
eH]Ro 25,6981 (n = 29) and eH]CP-101,606 (n = 7) against age, ranging from 62-91 years 
in the 8 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed (IY-0.17 in all cases) with the exception of the insular cortex eHJCP-
101,606 data where p=0.03, showing significance. The outer insular cortex eHJCP-101,606 
value showed borderline significance with p=0.06. The eH]CP-101,606 linear regression 
line was removed from Figure 4.20(H) due to the low n number, and would not have been 
statistically valid. The r values ranged from -0.005 ([3H]Ro 25,6981 external globus 
pallidus) to 0.81 (eH]CP-101,606 insular cortex), with the eH]CP-101,606 data 
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consistently showing better correlation to the linear regression than the eHJRo 25,698I 
data, possibly due to the lower n numbers. In all cases there were significantly higher levels 
of eHJRo 25,698I binding than eH]CP-I 0 I ,606 binding in each of the tissues analysed. 
The data in figure 4.20 (A-H) were further analysed for gender differences. Due to low n 
values in the eH]CP-1 0 1 ,606 male cohort, only the female data could be analysed. Figure 
4.2I (A-H) shows the specific binding levels in female control cases for CH]Ro 25,698I (n 
= I7) and eH]CP-1 0 I ,606 (n = 5) against age, ranging from 62-91 years in the 8 brain 
regions defined. There were no significant age-dependant changes in all brain regions 
analysed (IV-0.17 in all cases) with the exception of the claustrum and insular cortex 
eHJCP-101,606 data where p=0.08 in both cases, showing borderline significance, that is 
p~O.l. The eHJCP-I01,606 linear regression line was removed from graphs G and H due 
to the low n number, and would not have been statistically valid. The r values ranged from 
0.03 (eH]Ro 25,6981 outer insular cortex) to 0.89 ([3H]CP-101,606 cingulate cortex), with 
the eH]CP-1 01,606 data consistently showing better correlation to the linear regression 
than the eH]Ro 25,6981 data, possibly due to the lower n numbers. In all cases there were 
significantly higher levels of eH]Ro 25,6981 binding than eH]CP-1 01,606 binding in each 
of the tissues analysed. 
Figure 4.22 (A-G) shows the specific binding levels in male and female DLB cases for 
eH]Ro 25,6981 (n = 22) and eH]CP-101,606 (n = 12) against age, ranging from 69-92 
years in the 7 brain regions defined. There were no significant age-dependant changes in all 
brain regions analysed (IV-0.23 in all cases) with the exception of the outer insular cortex 
eH]CP-101,606 data where p=0.04, showing significance. The claustrum eH]Ro 25,6981 
value showed borderline significance with p=0.07. The r values ranged from 0.00 ([3H]CP-
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101,606 cingulate cortex) to -0.73 (eH]CP-101,606 outer insular cortex). In all cases there 
were significantly higher levels of eH]Ro 25,6981 binding than eH]CP-101,606 binding in 
each of the tissues analysed. 
The data in figure 4.22 (A-G) were further analysed for gender differences. Due to low n 
values in the eHJCP-101,606 female cohort, only the male data could be analysed. Figure 
4.23 (A-G) shows the specific binding levels in male DLB cases for eH]Ro 25,6981 (n = 
15) and eH]CP-101,606 (n = 8) against age, ranging from 69-92 years in the 7 brain 
regions defined. There were no significant age-dependant changes in all brain regions 
analysed (p~0.12 in all cases). The r values ranged from 0.00 (eH]Ro 25,6981 putamen) to 
0.70 (eH]CP-101,606 accumbens), with the eH]CP-101,606 data showing better 
correlation to the linear regression than the eH]Ro 25,6981 data in each tissue except the 
claustrum and insular cortex. In all cases there were significantly higher levels of eH]Ro 
25,6981 binding than eH]CP-101,606 binding in each ofthe tissues analysed. 
Figure 4.24 (A-F) shows the specific binding levels in male and female POD cases for 
eH]Ro 25,6981 (n = 9) and eH]CP-101,606 (n = 3) against age, ranging from 65-86 years 
in the 6 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed (p~0.15 in all cases). The eH]CP-1 01 ,606 linear regression line was 
removed from graphs B, C, E and F due to the low n number, and would not have been 
statistically valid. The r values ranged from 0.27 (eH]Ro 25,6981 insular cortex) to 0.96 
(eH]CP-101,606 insular cortex), with the eH]CP-101,606 data consistently showing better 
correlation to the linear regression than the eH]Ro 25,6981 data. The data could not be 
further analysed for gender differences due to low n numbers in the eH]CP-101,606 cohort. 
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In all cases there were significantly higher levels of eHJRo 25,6981 binding than eH]CP-
101,606 binding in each ofthe tissues analysed. 
Figure 4.25 (A-G) shows the specific binding levels in male and female AD cases for 
eH]Ro 25,6981 (n = 11) and eH]CP-101,606 (n = 2) against age, ranging from 78-91 years 
in the 7 brain regions defined. There were significant age-dependant changes in all brain 
regions analysed (p~0.01 in all cases) with the exception ofthe eHJRo 25,6981 claustrum 
and outer insular cortex data where p=0.17 and p=0.23 respectively, showing no 
significance. One observation from these results is a trend for the younger age cases in this 
AD group to show a higher level of binding than in the same younger age range for other 
disease states. This may be useful as an indication in the younger age group as a marker for 
a predisposition for AD. The eH]CP-1 01 ,606 linear regression line was removed from all 
the graphs due to the low n number, and would not have been statistically valid. The r 
values ranged from -0.39 (eH]Ro 25,6981 outer insular cortex) to -0.87 (eH]Ro 25,6981 
accumbens ). The data could not be further analysed for gender differences due to low n 
numbers in the eH]CP-1 01,606 cohort. In all cases there were significantly higher levels of 
eH]Ro 25,6981 binding than eH]CP-101,606 binding in each ofthe tissues analysed. 
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Figure 4.20 (A-D) Age-dependant absolute specific binding of [3H)Ro 
25,6981 and [3H)CP-101,606 in male and female control cases in (A) Caudate 
(B) Putamen (C) Claustrum and (D) Insular corteL 
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Figure 4.21 (A-D) Age-dependant absolute specific binding of [3H]Ro 
25,6981 and [3H]CP-101,606 in female control cases in (A) Caudate, (B) 
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4.5.4 Results (Figure 4.26 (A-l) to Figure 4.29 (A-F)) 
The same data as previously described (see graphs 4.20 (A-H) to graph 4.25 (A-G)) and 
summarised in table 4.2, were further analysed to compare age-dependant specific binding 
levels of eH]Ro 25,6981 and eH]CP-1 01 ,606 independently between control and disease 
state cases. The cases were analysed by correlating finoVmg binding with age at death of 
the subject (in years) for each case, and in each brain region defined. Estimated linear 
regression lines of best fit were produced using GraphPad Prism and are represented on 
each graph, indicating any age-dependant changes in binding levels in each tissue. The 
significance of the regression was determined from the generated p value, where p$0.05 
was considered to show a significant linear relationship between age and binding level. Due 
to limited availability of the eH]CP-101,606 ligand a smaller number of cases were 
analysed, resulting in low n numbers for some of the tissues. In these cases a linear 
regression line was not shown as it would not have been appropriate where n = <3. The 
generated correlation coefficient or r value shows how well the data fits to the regression 
line, where r = 1 shows strong correlation and r = 0 shows little or none. 
Figure 4.26 (A-I) shows the specific binding levels in male and female control (n = 26) and 
DLB (n = 22) cases (see table 4.2) for eH]Ro 25,6981 against age, ranging from 67-92 
years in the 9 brain regions defined. There were no significant age-dependant changes in all 
brain regions analysed in control and disease state cases (IY-0.23 in all cases) with the 
exception of the claustrum DLB data where p=0.07, showing borderline significance. The 
regression lines on each graph were very similar for both control and DLB data, showing a 
slight general decrease in binding levels in each of the tissues. The exception was the 
cingulate cortex (graph E), where binding levels increased with age in the control data set, 
242 
and decreased with age in the DLB data set. The r values ranged from 0.02 (DLB, putamen 
and control, external globus pallidus) to -0.41 (DLB, claustrum). 
The data in figure 4.26 (A-1) were further analysed for gender differences. Figure 4.27 (A-1) 
shows the specific binding levels in female control (n = 15) and DLB (n = 7) cases for 
eH]Ro 25,6981 against age, ranging from 62-91 years in the 9 brain regions defined. There 
were no significant age-dependant changes in all brain regions analysed in control and 
disease state cases (~0.18 in all cases) with the exception ofthe outer insular cortex DLB 
data where p=0.08, showing borderline significance, that is p=S0.1. The regression lines on 
each graph varied for both control and DLB data depending on the tissue. Control binding 
levels decreased as DLB binding levels increased in the caudate, whereas the opposite was 
true for the putamen, claustrum, insular cortex, cingulate cortex and outer insular cortex. 
Binding levels were highly similar in the external and internal globus pallidus, and both 
control and DLB levels increased with age in the nucleus accumbens. The r values ranged 
from 0.03 (control, outer insular cortex) to -0.84 (DLB, outer insular cortex), with the 
control data showing better correlation to the linear regression than the DLB data, with the 
exception of the internal globus pallidus and accumbens. 
Figure 4.28 (A-I) shows the specific binding levels in male control (n = 11) and DLB (n = 
15) cases for eH]Ro 25,6981 against age, ranging from 62-91 years in the 9 brain regions 
defined. There were no significant age-dependant changes in all brain regions analysed in 
control and disease state cases (p~.16 in all cases) with the exception ofthe claustrum and 
cingulate cortex control data where p=0.02 and p=0.03 respectively, showing significance. 
The external globus pallidus control data showed borderline significance with p=0.07. The 
regression lines on each graph were very similar for both control and DLB data in all the 
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tissues, with the exception of the cingulate cortex, where control binding levels increased 
with age as DLB binding levels decreased. The r values ranged from 0.00 (DLB, putamen) 
to 0.85 (control, cingulate cortex), with the DLB data showing better correlation to the 
linear regression than the control data, with the exception of the nucleus accumbens. 
Figure 4.29 (A-F) shows the specific binding levels in male and female control (n = 7) and 
DLB (n = 12) cases for eH]CP-101,606 against age, ranging from 62-92 years in the 6 
brain regions defined. There were no significant age-dependant changes in the brain regions 
analysed in control and disease state cases (IY-0.22 in all cases) with the exception of the 
insular cortex control data and DLB outer insular cortex data where p=0.03 and p=0.04 
respectively, showing significance. The control outer insular cortex data showed borderline 
significance with p=0.06. The regression lines on each graph were very similar for both 
control and DLB caudate and cingulate cortex data showing a slight increase with age in 
both data sets. All other tissues showed a decrease in binding with DLB as control binding 
increased with age. The r values ranged from 0.00 (DLB, cingulate cortex) to 0.81 (control, 
insular cortex). The data were not further analysed for gender differences due to the low n 
numbers in the CP-101,606 cohort. 
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4.5.5 Results (Figure 4.30 (A- I) to 4.32 (A-F)). 
Figure 4.30 (A-1) shows the specific binding levels in male and female control (n = 26) and 
PDD (n = 7) cases (see table 4.2) for eH]Ro 25,6981 against age, ranging from 67-92 years 
in the 9 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed in control and disease state cases (JY-0.15 in all cases) with the exception 
of the external globus pallidus PDD data where p=0.09, showing borderline significance. 
The regression lines on each graph were very similar for both control and DLB data in the 
cingulate cortex and external globus pallidus, showing a slight increase in binding levels 
with age. All other tissues showed a sharp increase in PDD binding with age as the control 
binding levels either slightly decreased, or in the case of the accumbens, slightly increased. 
The PDD regression line was removed from graph H due to the low n number, as it would 
not have been statistically valid. The r values ranged from 0.02 (control, external globus 
pallidus) to 0.98 (PDD, external globus pallidus). 
The data in figure 4.30 (A-1) were further analysed for gender differences. Figure 4.31 (A-F) 
shows the specific binding levels in male control (n = 11) and PDD (n = 6) cases (see table 
4.2) for eH]Ro 25,6981 against age, ranging from 67-91 years in the 6 brain regions 
defined. There were no significant age-dependant changes in all brain regions analysed in 
control and disease state cases (JY-0.17 in all cases) with the exception of the control 
claustrum and cingulate cortex where p=0.02 and p=0.03 respectively showing significance. 
The regression lines on each graph were similar for both control and PDD data in the 
caudate and cingulate cortex where both showed an increase in binding with age. All other 
tissues showed an increase in PDD binding with age as the control binding levels decreased. 
The r values ranged from 0.18 (control, caudate) to 0.85 (control, cingulate cortex). Due to 
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low n values in the eH]Ro 25,6981 female PDD cohort, only the male data could be 
analysed. 
Figure 4.32 (A-F) shows the specific binding levels in male and female control (n == 7) and 
PDD (n == 3) cases (see table 4.2) for eH]CP-101,606 against age, ranging from 62-87 
years in the 6 brain regions defined. There were no significant age-dependant changes in all 
brain regions analysed in control and disease state cases (~0.18 in all cases) with the 
exception of the control insular cortex where p=0.03 showing significance. The control 
outer insular cortex showed borderline significance with p==0.06. The regression lines on 
graphs B, C, E and F were removed due to the low n numbers, and would not have been 
statistically valid. The regression lines were similar for both control and POD data in the 
caudate and insular cortex in that both showed an increase in binding with age. The r values 
ranged from 0.36 (control, caudate) to 0.96 (PDD, insular cortex). The data could not be 
further analysed for gender differences due to low n numbers in both the control and PDD 
cohorts. 
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4.5.6 Results (Figure 4.33 (A-I) to 4.35 (A-F)). 
Figure 4.33 (A-1) shows the specific binding levels in male and female control (n = 26) and 
DLBPDD (n = 10) cases (see table 4.2) for eH]Ro 25,6981 against age, ranging from 67-
91 years in the 9 brain regions defined. There were no significant age-dependant changes in 
all brain regions analysed in control and disease state cases (p;:::0.12 in all cases) with the 
exception of the insular cortex DLBPDD data where p=0.08, showing borderline 
significance. The control and DLBPDD regression lines showed a similar pattern on graphs 
A, B, C, D and F, showing an increase in DLBPDD binding levels as control binding levels 
decrease with age. Both control and DLBPDD binding levels increased with age in the 
cingulate cortex and accumbens, while both binding levels decreased with age in the 
external and internal globus pallidus. The r values ranged from 0.02 (control, external 
globus pallidus) to 0.74 (DLBPDD, internal globus pallidus), with the control data showing 
better correlation to the linear regression than the DLBPDD data in all tissues. 
The data in figure 4.33 (A-1) were further analysed for gender differences. Figure 4.34 (A-1) 
shows the specific binding levels in female control (n = 15) and DLBPDD (n = 7) cases for 
eH]Ro 25,6981 against age, ranging from 62-91 years in the 9 brain regions defined. There 
were no significant age-dependant changes in all brain regions analysed in control and 
disease state cases ~0.17 in all cases) with the exception of the insular cortex DLBPDD 
data where p=0.06, showing borderline significance. The DLBPDD regression lines 
showed an increase with age in all the tissues except the external and internal globus 
pallidus. The control regression lines showed an increase in binding levels with increasing 
age, with the exception of the caudate and putamen. The r values ranged from 0.03 (control, 
outer insular cortex) to 0.77 (DLBPDD, accumbens), with the control data showing better 
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correlation to the linear regression than the DLBPDD data in all tissues except the external 
globus pallidus. 
Figure 4.35 (A-F) shows the specific binding levels in male control (n = 11) and DLBPDD 
(n = 5) cases for eH]Ro 25,6981 against age, ranging from 62-87 years in the 6 brain 
regions defined. There were no significant age-dependant changes in all brain regions 
analysed in control and disease state cases ~0.17 in all cases) with the exception of the 
control claustrum and cingulate cortex data where p=0.02 and p=0.03 respectively, showing 
significance. The DLBPDD regression lines decreased with age in all the tissues except the 
putamen, whereas the control regression lines decreased in all but the caudate and cingulate 
cortex. The r values ranged from 0.18 (control, caudate) to 0.85 (control, cingulate cortex). 
Due to low n numbers, the data for eH]CP-1 01 ,606 DLBPDD cases could not be analysed. 
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4.5.7 Results (Figure 4.36 (A-Il to Figure 4.38 (A-F)) 
Figure 4.36 (A-1) shows the specific binding levels in male and female control (n = 26) and 
AD (n = 10) cases (see table 4.2) for eH]Ro 25,6981 against age, ranging from 67-91 years 
in the 9 brain regions defined. There were significant age-dependant changes in all brain 
regions analysed in the AD cases (p:50.02 in all cases) with the exception of the claustrum, 
external and internal globus pallidus, where p=O.l6, p=0.07 (borderline significance) and 
p=0.42 respectively. There were no significant age-dependant changes in all the regions 
analysed in the control data. The AD regression lines showed a sharp decrease with age in 
all the tissues, whereas the control data varied depending on the tissue. The r values ranged 
from 0.02 (control, external globus pallidus) to 0.98 (AD, cingulate cortex). 
The data in figure 4.36 (A-1) were further analysed for gender differences. Figure 4.37 (A-
G) shows the specific binding levels in female control (n = 15) and AD (n = 7) cases for 
eH]Ro 25,6981 against age, ranging from 62-91 years in the 7 brain regions defined. There 
were significant age-dependant changes in all brain regions analysed in the AD cases 
(p:50.03 in all cases) with the exception of the claustrum and outer insular cortex data where 
p=0.23 and p=0.39 respectively. For the cingulate cortex p=O.IO, showing borderline 
significance. As with the male and female graphs combined, the AD regression lines 
showed a sharp decrease with age in all the tissues, whereas the control data varied 
depending on the tissue. The r values ranged from 0.03 (control, outer insular cortex) to 
0.89 (AD, nucleus accumbens). 
Figure 4.38 (A-F) shows the specific binding levels in male and female control (n = 7) and 
AD (n = 2) cases for eH]CP-1 01 ,606 against age, ranging from 62-87 years in the 6 brain 
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regions defined. There were no significant age-dependant changes in all brain regions 
analysed in the control cases (p~0.22 in all cases) with the exception of the insular cortex 
where p=0.03, showing significance, and the outer insular cortex where p==0.06, showing 
borderline significance. The AD regression lines could not be shown due to the low n 
numbers, and would not have been statistically valid. The r values ranged from 0.36 
(control, caudate) to 0.81 (control, insular cortex). The data could not be further analysed 
for gender differences due to the low n numbers. 
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4.5.8 Results (Figure 4.39 (A-I) to Figure 4.44 (A-F)) 
The data were then further analysed to show specific binding levels of both eH]Ro 25,6981 
and eH]CP-101,606 individually in various brain regions, analysing all control and disease 
state groups separately from each other. Radioligand binding levels in frnol/mg were 
correlated with age at death of the subject (in years) for each case, and in each brain region 
defmed, to look for gender differences in the tissues. Estimated linear regression lines of 
best fit were produced using GraphPad Prism and are represented on each graph, indicating 
any age-dependant changes in binding levels in each tissue. The significance of the 
regression was determined from the generated p value, where p50.05 was considered to 
show a significant linear relationship between age and binding level. Due to limited 
availability of the eH]CP-101,606 ligand a smaller number of cases were analysed, 
resulting in low n numbers for some of the tissues. In these cases a linear regression line 
was not shown as it would not have been appropriate where n = <3. The generated 
correlation coefficient or r value shows how well the data fits to the regression line, where r 
= 1 shows strong correlation and r = 0 shows little or none. 
Figure 4.39 (A-1) shows the specific binding levels in female (n = 17) and male (n = 12) 
control cases (see table 4.1) for eH]Ro 25,6981 against age, ranging from 62-91 years in 
the 9 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed (IY-0.17 in all cases) with the exception of the male claustrum and the 
male cingulate cortex data where p=0.02 and p=0.03 respectively, showing significance. 
Interestingly, the male claustrum binding level significantly decreased with age, whereas 
the male cingulate cortex binding level significantly increased with age. The male external 
globus pallidus data gave p=0.07, showing borderline significance. There did not appear to 
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be any trends emerging from the data as the regression lines on each graph varied a great 
deal for male and female cases and depending on which tissue was being analysed. The r 
values ranged from 0.03 (female, outer insular cortex) to 0.85 (male cingulate cortex). 
Figure 4.40 (A-F) shows the specific binding levels in female (n = 5) and male (n = 2) 
control cases (see table 4.1) for eH]CP-101,606 against age, ranging from 62-87 years in 
the 6 brain regions defined. Due to the low n numbers for the male data the regression lines 
could not be drawn, although the female regression lines in each tissue showed an increase 
in binding level with age, where }12:0.17 in each case. The claustrum and insular cortex 
showed borderline significance where p=0.08in both cases. The r values ranged from 0.29 
(female, caudate) to 0.88 (female cingulate cortex). 
Figure 4.41 (A-1) shows the specific binding levels in female (n = 7) and male (n = 15) 
DLB cases (see table 4.1) for eH]Ro 25,6981 against age, ranging from 69-92 years in the 
9 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed (p~0.16 in all cases) with the exception of the female outer insular cortex 
where p=0.08, showing borderline significance. As with the data in figure 4.39 (A-1), the 
regression lines on each graph varied a great deal for male and female cases and depending 
on which tissue was being analysed, and no clear age dependant trends were seen. The r 
values ranged from 0.00 (male, putamen) to -0.84 (female outer insular cortex). 
Figure 4.42 (A-G) shows the specific binding levels in female (n = 4) and male (n = 8) 
DLB cases (see table 4.1) for eH]CP-101,606 against age, ranging from 69-92 years in the 
7 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed ~0.12 in all cases). The female outer insular cortex regression line was 
not shown due to a low n number. Again, the regression lines on each graph varied a great 
deal for male and female cases and depending on which tissue was being analysed, and no 
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clear age dependant trends were seen. The accumbens data showed the most distinct 
difference between female and male data sets, with the female binding level trend 
decreasing with age, and the male binding level increasing with age. The r values ranged 
from 0.01 (female, caudate) to -0.88 (female accumbens). 
Figure 4.43 (A-F) shows the specific binding levels in female (n = 7) and male (n = 5) 
DLBPDD cases (see table 4.1) for eH]Ro 25,6981 against age, ranging from 64-89 years in 
the 6 brain regions defined. There were no significant age-dependant changes in all brain 
regions analysed (JY-0.17 in all cases) with the exception of the female insular cortex where 
p=0.06, showing borderline significance. Unlike the previous data, some clear gender 
differences with age were seen. The female regression lines for each of the 6 tissues 
showed an increase in binding levels with age, whereas the male data showed a decrease in 
binding levels with age in all cases except the putamen. The r values ranged from -0.21 
(male, claustrum) to 0.73 (female insular and cingulate cortex). 
Figure 4.44 (A-F) shows the specific binding levels in female (n = 7) and male (n = 4) AD 
cases (see table 4.1) for eH]Ro 25,6981 against age, ranging from 78-91 years in the 6 
brain regions defined. There were significant age-dependant changes in the female caudate, 
putamen, insular cortex and male cingulate cortex. The male caudate and female cingulate 
cortex data showed borderline significance with p=0.09 and p=O.l respectively. All other 
tissues showed no significance with p~0.20. A clear trend can be seen for both the male and 
female data, showing a decrease in binding levels for both as age increases. The r values 
ranged from -0.16 (male, claustrum) to -0.99 (male, cingulate cortex). 
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Figure 4.41 (A-E) Age-dependant specific binding of (3H)Ro 25,6981 in Male 
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4.5.9 Results (Figure 4.45 (A-D to Figure 4.50 (A-F)) 
The data from figure 4.39 (A-I) were further analysed to show the mean average specific 
binding (fmoVmg) ± SD of eH]Ro 25,6981 in female and male control cases for n 
determinations in the 9 brain regions defined, shown in figure 4.45 (A-I). In each of the 9 
tissues, except the internal globus pallidus, the mean male binding value appeared to be 
higher than the mean female binding value, although analysis showed this was not 
statistically significant. The claustrum, internal and external globus pallidus binding levels 
in both male and female cases were lower than the other tissues, an observation seen in 
previous graphs. 
A similar analysis was performed on the data from figure 4.40 (A-F), showing the mean 
average specific binding (fmoVmg) ± SD of eH]CP-101,606 in female and male control 
cases for n determinations in the 6 brain regions defined, shown in figure 4.46 (A-F). In 
each of the tissues, except the claustrum, the mean male binding value appeared to be 
higher than the mean female binding value, although statistical analysis showed this not to 
be significant. As for figure 4.45 (A-I), the claustrum binding levels in both male and 
female cases were lower than the other tissues. The specific binding values for the CP-
101,606 ligand were always lower than those seen for the Ro 25,6981 ligand, in all the 
tissues. 
Again, the data from figure 4.41 (A-I) were further analysed to show the mean average 
specific binding (fmoVmg) ± SD of eHJRo 25,6981 in female and male DLB cases for n 
determinations in the 9 brain regions defined, shown in figure 4.47 (A-1). In each of the 
tissues represented on graphs A, B, F, G and I, the mean male binding levels were higher 
than those of the females, although statistically not significant. However, mean binding 
levels in the female data were higher in the tissues represented on graphs C, D, E and H, 
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but again these differences were not statistically significant when analysed by a student's 
unpaired t-test. As for figure 4.45 (A-1), the claustrum, internal and external globus pallidus 
binding levels in both male and female cases were lower than the other tissues. 
The data from figure 4.42 (A-G) were further analysed to show the mean average specific 
binding (fmol/mg) ± SD of eH]CP-101,606 in female and male DLB cases for n 
determinations in the 7 brain regions defined, shown in figure 4.48 (A-G). The mean male 
binding values appeared to be lower than the mean female binding values in all tissues 
except the caudate and putamen. However, t-test analysis showed that there was no 
significant difference in levels of binding between male and female data sets in all the 
tissues except in the accumbens (p=0.02). The claustrum binding levels in both male and 
female cases were lower than the other tissues. 
The data from figure 4.43 (A-F) were analysed to show the mean average specific binding 
(fmollmg) ± SD of eHJRo 25,6981 in female and male DLBPDD cases for n 
determinations in the 6 brain regions defined, shown in figure 4.49 (A-F). The mean male 
binding values were significantly lower than the mean female binding values in the caudate 
(p=0.02) and putamen (p=0.04) but were not statistically different in all other tissues. The 
claustrum binding levels in both male and female cases were lower than the other tissues. 
Figure 4.50 (A-F) shows the mean average specific binding (fmol/mg) ± SD of eH]Ro 
25,6981 in female and male AD cases for n determinations in the 6 brain regions defined. 
The data was taken from the previous figure 4.44 (A-F). There were no significant 
differences in the binding levels between male and female data sets in any of the regions 
analysed. The claustrum binding levels in both male and female cases were lower than the 
other tissues. 
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Figure 4.45 (A-E) Mean average specific binding (fmollmg) ± SD of [3H]Ro 
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4.5.10 Results (Figure 4,51 (A-F) to Figure 4.54 (A-F)) 
The clinical data corresponding to the cases summarised in tables 4.4 to 4. 7 (that is, DLB, 
POD, DLBPDD and AD cases respectively) were collated and are summarised in table 4.8 
(DLB cases), table 4.9 (POD cases), table 4.10 (DLBPDD cases) and table 4.11 (AD cases). 
They show the relevant scores for the MMSE (mini mental state examination, see section 
4.3), MTS (mental test score, see section 4.3.1) and UPDRS scores (Unified Parkinson 
disease rating scale, see section 4.4). Data relating to depression, delusions, dementia and 
visual hallucinations experienced by each subject were also studied. The severity of the 
symptoms experienced were measured on the following scale, 0 = none, 1 = mild, 2 = 
severe, and are indicative of the last assessment before death of the subject. In each case 
and in each tissue studied, the specific binding levels of eH]Ro 25,6981 data were shown 
against the relevant clinical data score. In the case of the MMSE, MTS and UPDRS data, 
the score could be any value in a given range; therefore each case is represented on the 
graphs. The depression, delusion, dementia and visual hallucination data has been shown 
for each of the 0-2 score options, giving the mean score ± SD against binding levels in 
fmol/mg. Although in the majority of cases studied clinical data was available, 
unfortunately not all cases had the relevant data, and therefore only those with the data 
present are shown. This reduction in n number meant only the eH]Ro 25,6981 labelled 
cases were used for the further symptom correlation studies. There were too few cases with 
the appropriate clinical data in the eH]CP-101,606 cohort, and so were therefore not used. 
The Lewy body disease cases represented by DLB, PDD and DLBPDD cases have been put 
together as they are clinically well defined and show similar results, however the AD cases 
have been kept separate since they show some interesting trends not seen in the other 
disease states. Estimated linear regression lines of best fit were produced using GraphPad 
Prism and are represented on each graph, indicating any changes in binding levels in each 
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tissue with increasing clinical score. The significance of the regression was determined 
from the generated p value, where pS0.05 was considered to show a significant linear 
relationship between clinical score and binding level. The generated correlation coefficient 
or r value shows how well the data fits to the regression line, where r = 1 shows strong 
correlation and r = 0 shows little or none. 
Figure 4.51 (A-F) shows the specific binding levels in female and male DLB, PDD and 
DLBPDD (n = 22) cases (see tables 4.8- 4.10) for eH]Ro 25,6981 against MMSE score, in 
the 6 brain regions defined. The general trend in all the graphs showed a decrease in 
binding level with an increase in MMSE score, although there were no significant changes 
in MMSE score with increasing binding levels in all brain regions analysed ~0.06 in all 
cases). The insular cortex showed border-line significance with p=0.06 with a decrease in 
binding with increasing score. The r values ranged from -0.11 (caudate) to -0.41 (insular 
cortex). Figure 4.51(a) shows the specific binding levels for PDD (n = 6) cases (see table 
4.9) for eH]Ro 25,6981 against MTS score in the 5 brain regions defined. The data appears 
to show a decrease in binding with increasing MTS score although analysis has shown this 
not to be statistically significant (p ~ 0.18). This may be due to low n numbers. The r values 
ranged from -0.5 (putamen) to -0.63 (insular cortex). Figure 4.52 (A-F) shows the specific 
binding levels in female and male AD (n = 8) cases (see table 4.11) for eH]Ro 25,6981 
against MMSE score, in the 6 brain regions defined. The general trend seen in graphs A, B, 
E and F showed a decrease in binding level with an increase in MMSE score. Graphs C and 
D showed an increase in binding level with an increase in MMSE score, although there 
were no significant changes in MMSE score against binding levels in all the brain regions 
analysed ~0.20 in all cases). The r values ranged from 0.06 (cingulate cortex) to -0.56 
(claustrum). 
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Figure 4.53 (A-F) shows the specific binding levels in female and male DLB, POD and 
DLBPDD (n = 26) cases (see tables 4.8- 4.10) for eH]Ro 25,6981 against UPDRS score, in 
the 6 brain regions defined. There were no significant changes in UPDRS score with 
changing binding levels in all brain regions analysed ~0.14 in all cases). The cingulate 
cortex data showed a decrease in binding level as UPDRS score increased, although all the 
other tissues showed an increase in binding level with increasing UPDRS score. The r 
values ranged from -0.30 (cingulate cortex) to 0.34 (claustrum). Figure 4.54 (A-F) shows 
the specific binding levels in female and male AD (n = 8) cases (see table 4.11) for eH]Ro 
25,6981 against UPDRS score, in the 6 brain regions defined. The general trend seen in all 
the graphs A-F showed a decrease in binding level with an increase in UPDRS score, with 
the caudate (p=0.05) and putamen (p=0.04) regression lines showing significance. The 
insular cortex, cingulate cortex and outer insular cortex showed borderline significance 
with p=0.07, p=0.06 and p=0.06 respectively. The r values ranged from -0.61 (claustrum) to 
-0.78 (cingulate cortex). 
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4.5.11 Results (Figure 4.55 (A-F) to Figure 4.62 (A-F)) 
Figure 4.55 (A-F) shows the mean specific binding levels ± SD (fmol/mg) in female and 
male DLB, PDD and DLBPDD (n = 19) cases (see tables 4.7- 4.10) for eH]Ro 25,6981 
against depression score, in the 6 brain regions defined. There were no significant 
differences between binding levels in any of the brain regions shown, or between the 
depression scores in the tissues individually. The claustrum binding levels for all scores 
were slightly lower than in other tissues. The binding levels tended to be slightly lower for 
the score of 2 compared to 0 or I score, but was not always the case. The same analysis was 
carried out for the AD cases, see figure 4.56 (A-F), showing the mean specific binding 
levels± SD (fmol/mg) in female and male AD (n = 8) cases (see table 4.11) for eHJRo 
25,6981 against depression score, in the 6 brain regions defined. There were no significant 
differences in levels of binding for depression score 2 compared to 0 in all the tissues 
studied, although the mean binding value for score 2 was always slightly higher than for 
score 0. The claustrum binding levels for all scores were slightly lower than in other tissues. 
Figure 4.57 (A-F) shows the mean specific binding levels± SD (fmoVmg) in female and 
male DLB, PDD and DLBPDD (n = 25) cases (see tables 4.7- 4.10j for eHJRo 25,6981 
against delusion score, in the 6 brain regions defined. The mean binding levels tended to be 
slightly higher for the score of I compared to 0 or 2 score in each tissue, although these 
differences were not significant. Binding levels were very similar in the brain regions 
shown and between the depression scores in the tissues individually. The claustrum binding 
levels for all scores were lower than in other tissues. The same analysis was carried out for 
the AD cases, see figure 4.58 (A-F), showing the mean specific binding levels ± SD 
(fmollmg) in female and male AD (n = 9) cases (see table 4.11) for eH]Ro 25,6981 against 
delusion score, in the 6 brain regions defined. There were no significant differences in 
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levels of binding for depression score 0, 1 or 2 in all the tissues studied. The claustrum 
binding levels for all scores were lower than in other tissues. 
The dementia data for the female and male DLB, PDD and DLBPDD cases (n = 40) is 
shown in figure 4.59 (A-F) against mean specific binding levels± SD (fmollmg) for each of 
the 6 brain regions defined. As with the previous graphs, no significant differences have 
emerged between binding levels for each score, or between the different regions analysed. 
The same is true for the female and male AD cases (n = 9), see figure 4.60 (A-F). Low n 
numbers make the comparisons statistically invalid. 
Figure 4.61 (A-F) shows the mean specific binding levels± SD (fmollmg) in female and 
male DLB, PDD and DLBPDD (n = 29) cases (see tables 4.7- 4.10) for eH]Ro 25,6981 
against visual hallucination score, in the 6 brain regions defined. There were no significant 
differences between binding levels in any of the brain regions shown with the exception of 
the Outer insular cortex where p=0.001 between scores 0 and 1. The claustrum binding 
levels for all scores were lower than in other tissues. The female and male AD cases (n = 
1 0), shown in figure 4.62 (A-F) shows no significant differences in binding level as the 
clinical score increases. 
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Figure 4.59 Dementia score against [3H]Ro 25,6981 specific binding 
(fmollmg) for DLB, PDD and DLBPDD cases in (A) Caudate (B) Putamen 
(C) Insular Cortex (D) Cingulate Cortex (E) Outer Insular Cortex and (F) 
Claustrum. 
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Figure 4.60 Dementia score against [3H)Ro 25,6981 specific binding 
(fmollmg) for AD cases in (A) Caudate (B) Putamen (C) Insular Cortex 
(D) Cingulate Cortex (E) Outer Insular Cortex and (F) Claustrum. 
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Figure 4.61 Visual Hallucination score against [3H]Ro 25,6981 specific 
binding (fmollmg) for DLB, PDD and DLBPDD cases in (A) Caudate (B) 
Putamen (C) Insular Cortex (D) Cingulate Cortex (E) Outer Insular Cortex 
and (F) Claustrum. 
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Figure 4.62 Visual Hallucination score against [3H]Ro 25,6981 specific binding 
(fmollmg) for AD cases in (A) Caudate (B) Putamen (C) Insular Cortex (D) 
Cingulate Cortex (E) Outer Insular Cortex and (F) Claustrum. 
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4.6 Discussion 
The autoradiographical assays performed in this study have been to distinguish and 
quanticy different populations of NMDAR2B subunit-containing NMDA receptors, 
visualised using eH]Ro 25,6981 and eH]CP-101,606, NR2B-selective ligands. A range of 
brain structures implicated in the characteristic symptoms of DLB, PDD and AD were 
investigated. For example, the striatum (consisting of the caudate nucleus and putamen) is 
known for its role in the planning and modulation of movement pathways, but is also 
involved in a variety of other cognitive processes involving executive function. This area 
may be affected in neurological disorders where movement is impaired, such as PD. The 
cerebral cortex is involved in many complex brain functions including memory, attention, 
perceptual awareness, language and consciousness. More specifically, the cingulate cortex 
is thought to be associated with mood and emotions, and the insular cortex is believed to 
process convergent information to produce an emotionally relevant context for sensory 
experience, such as anxiety and pain. These are brain areas whose functions are affected by 
dementia and chronic neurodegenerative diseases where cognition steadily declines. The 
main focus has been to determine any changes in the NR2B receptor subtypes in relation to 
age and gender in control, DLB, PDD, DLBPDD and AD cases. 
Over the last several years, an increasing number of reports have demonstrated the 
importance of the NR2B subunit in a variety of functions such as learning, memory 
processing and synaptic plasticity, as well as being involved in a number of human 
disorders (Loftis & Janowsky, 2003). Perturbations in glutamate neurotransmission and 
glutamate receptor activation may be fundamental to a variety of neurological disorders. 
Excessive release of glutamate contributing to excitotoxic neuronal death has been 
implicated as an etiologic mechanism in anoxic-ischemic injury, epilepsy and chronic 
neurodegenerative disorders such as Alzheimer's disease (Sze et al., 2001). Most 
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researchers agree that NMDARs produce neurotoxicity via rapid Ca2+ influx leading to 
cellular Ca2+ overload (Zhou & Baudry, 2006). Abnormal function ofNMDA receptors has 
been suggested to be correlated with the pathogenesis of Parkinson's disease (PD) as well 
as with the development of L-DOPA induced dyskinesia (Gardoni et al., 2006). NMDA 
receptor antagonists exert a beneficial effect in experimental models of PD (Nash et al., 
2000; Loschmann et al., 2004) and they are also effective in blocking the development of 
L-DOPA-induced dyskinesias (Wessell et al., 2004). NMDA receptors have several 
important functions in the motor circuits of the basal ganglia, and are viewed as important 
targets for the development of new drugs to prevent or treat Parkinson's disease (PD). 
NMDA receptors present in the striatum are crucial for dopamine-glutamate interactions. 
The abundance, structure, and function of striatal receptors are altered by the dopamine 
depletion and further modified by the pharmacological treatments used in PD. In animal 
models, NMDA receptor antagonists are effective antiparkinsonian agents and can reduce 
the complications of chronic dopaminergic therapy. Use of these agents in humans has been 
limited because of the adverse effects associated with non-selective blockade of NMDA 
receptor function, but the development of more potent and selective pharmaceuticals holds 
the promise of an important new therapeutic approach for PD (Hallett & Standaert 2004). 
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative 
dementia in older people and is a primary, neurodegenerative dementia sharing clinical and 
pathological characteristics with both Parkinson's disease (PD) and Alzheimer's disease 
(AD). NMDA receptors are known to play a pivotal role in synaptic mechanisms of 
learning and memory and NR2B ligands were chosen for this study since the NR2B subunit 
is a potential drug target for the treatment of such neurological disorders. 
Ro 25,6981, a Roche compound, is an NR2B-selective antagonist, which binds to the 
ifenprodil binding site (Grimwood et al., 2000; Mutel et al., 1998, Lynch et al., 2001). 
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Fischer et al. ( 1997) studied the characteristics of the interaction between Ro 25,6981 and 
NMDA receptors in a variety of different tests in vitro. They demonstrated that Ro 25,6981 
is a highly selective, activity dependant blocker ofNMDA receptors that contain the NR2B 
subunit, with potent neuroprotective effects in vitro. CP-1 01,606, a Pfizer compound, acts 
to inhibit NMDA receptor channel activity (Mott et al, 1998), has been shown to be a 
potent neuroprotectant selective for forebrain neurons. Autoradiography indicates the CP-
1 01 ,606 binding site is located in forebrain, most notably in hippocampus and the outer 
layers of cortex (Menniti et al., 1997). Work carried out by Chazot et a/ (2002) has 
provided evidence that CP-101,606 may represent a class of NR2B-directed NMDA 
receptor antagonist whose binding is affected significantly by the presence of another NR2 
subunit type within the receptor complex. 
4.6.1 Control Data 
The first aim of this study was to determine the distribution pattern of ligand binding in the 
normal human brain and whether there were any differences in binding levels between the 
two NMDAR2B receptor ligands. 29 control cases were used representing normal ageing 
ranging from 62 -91 years. Figure 4.1(a) shows the agonal state score against eH]Ro 
25,6981 specific binding in the control data set for the putamen and insular cortex. There 
was no significant difference seen in the binding densities between agonal state scores, 
suggesting rapid or prolonged death does not significantly affect NR2B-containing NMDA 
receptor density in post-mortem tissue. Figure 4.3 and 4.4 show radioligand binding in 
control cases, labelling NR2B-containing receptors in distinct brain regions. These data 
agree with and support similar findings in previous experiments. For example, 
autoradiographical studies have shown high density NR2B binding in the rat cerebral cortex, 
hippocampus, dentate gyrus, caudate, putamen, globus pallidus and thalamus, with low 
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binding levels in the cerebellum (Mutel et al., 1998). NMDA receptor high-affinity 
eH]ifenprodil binding sites were found in the cortex, hippocampus, striatum and thalamus 
of the rat brain, with little or no labelling in the cerebellar region (Nicolas & Carter, 1994). 
Menniti et a/ (1997) used autoradiography to indicate the CP-101,606 binding site is 
localized in forebrain, particularly in hippocampus and the outer layers of cortex. Chapter 3, 
section 3.1 describes the regions where NR2B binding was high in the mouse brain. High 
ligand binding levels were seen in the CA 1, CA3, granule layer of the dentate gyrus, 
entorhinal cortex and outer layers ofthe frontal cortex. Chapter 3, section 3.2.3 also shows 
that in the rat brain, the higher binding levels of eH]Ro 25,6981 and eH]CP-1 01,606 were 
found in the CAI, CA3, granule layer ofthe dentate gyrus, entorhinal cortex and outer layer 
of the frontal cortex. Figure 4.3 and 4.4 also show clear differences in the levels of binding 
between the two ligands in control tissues, with the eH[Ro 25,6981 sections visibly darker 
than the eH]CP-101,606, indicating higher binding levels, and therefore a higher presence 
of NR2B-containing receptor. These binding differences can be clearly seen in figure 4.9 
(A-C) showing that in all the tissues, the levels of binding were significantly greater for 
eH[Ro 25,6981 than for eH]CP-101,606 when control male and female data were 
presented both together and individually. Table 4.13 shows that CP-101,606 binding 
relative to Ro 25,6981 was always less than 50% in pooled and separate male and female 
data sets, showing limited evidence for gender bias in the data. The percentage of CP-
101,606 binding relative toRo 25,6981 was variable between the regions (8-45% pooled 
male and female, 24-45% female only data and 20-47% male only data), suggesting a 
different proportion of the NR2B subtype population is present in each of the different 
tissues. These findings provide evidence that eH]CP-1 01,606 labels a discrete population 
of NR2B-containing NMDA receptors in all the brain regions studied, consistent with 
previous studies by Chazot et a/ (2002). 
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The control data were further analysed for age-related changes, a phenomenon already 
observed in animal models, and to see whether there were any gender differences in the 
receptor level in normal ageing. Wenk et al (1991) demonstrated a significant decrease in 
NMDA receptor binding in the brains of aged rats and rhesus monkeys. A significant 
decrease in the mRNA expression of the NR2B subunit was also seen in the prefrontal 
cortex and caudate nucleus between young and old macaque monkeys, results similar to 
those previously seen in C57BL/6 mice during ageing (Bai et al., 2004). Declines in spatial 
memory abilities are seen in humans, monkeys and rodents, and are thought to be related to 
changes in NR2B subunit expression. Peters et al. (2000) reported age-related alterations in 
primary visual cortex myelin in monkeys. A significant correlation was seen between the 
breakdown of the myelin and the impairments in cognition exhibited by individual 
monkeys. Age-related decreases of the NMDA receptor complex in the rat cerebral cortex 
and hippocampus have also been described by Tamaru et al. (1991 ). The evidence suggests 
age does effect NMDA receptor expression in animal models of normal ageing; therefore 
the purpose of this part of the study was to investigate potential NR2B subunit expression 
changes in normal human ageing. Figure 4.20 shows no significant changes in level of 
eH[Ro 25,6981 or eHJCP-101,606 binding in any region over the age range studied, with 
the exception of the eH]CP-101,606 insular and outer insular cortex data, showing p=0.03 
(significance) and p=0.06 (border-line significance) respectively. The data for these two 
regions shows an increase in binding as age increases, suggesting an increase in NR2B-
subunit containing receptor population with age. This is interesting since the published 
literature suggests overall NR2B expression decreases with age in normal ageing animal 
models. A similar observation is seen in Figure 4.21 where the female control eH[Ro 
25,6981 and eH]CP-101,606 binding data is shown against age. There were again no 
significant changes in binding levels with age for either of the two ligands, with the 
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exception of the eH]CP-1 01 ,606 claustrum and insular cortex data, where p=0.08 (border-
line significance) in both cases. As with the pooled insular and outer insular cortex male 
and female data in Figure 4.21, there is again an increase in binding level in these two 
regions with increasing age. If the overall NR2B subtype population (NR 1/2B/2A, or 
2B/2C and 2B/2D) is said to decrease with age (Wenk et al. 1991, Bai et al. 2004) and the 
NR2B subtype population (NR112B) is shown in this study to increase with age (shown by 
the CP-1 01 ,606 binding), then a possible switch in a class of NR2B subtype population 
with age may be occurring to compensate for these changes. An early age dependant switch 
was also detected in the rat, see Figure 3.2.3.1 0 in Section 3.2.3, Chapter 3. Figure 4.20-
4.21 also clearly show the absolute binding levels of eHJRo 25,6981 were significantly 
higher than the eH]CP-1 01,606 binding levels in pooled male and female, and female only 
data sets. 
The data were analysed for gender differences over the age range. Figure 4.39 shows the 
separate control male and female binding levels for eH]Ro 25,6981 against age. There 
were no significant age-related differences in the regions analysed except in the male 
claustrum and external globus pallidus (p=0.02 and p=0.07 respectively, where binding 
decreased with age) and male cingulate cortex (p=0.03 binding increased with age). The 
function of the claustrum is not completely known although it may be one of the most 
probable key components of consciousness (Crick & Koch 2005), and the cerebral cortex is 
known to be related to memory, attention, perceptual awareness and consciousness. 
Changes in NR2B receptors in these areas with age may be important in cognitive changes 
seen with increasing age. Figure 4.40 shows the separate control male and female binding 
levels for eH]CP-1 01,606 versus age. There were no significant changes seen in binding 
with increasing age. The female data showed only border-line significance (p=0.08) in the 
claustrum and insular cortex. The same data in Figure 4.39 and 4.40 is represented as a 
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mean average specific binding value (±SD) for female and male data sets in Figure 4.45 
and 4.46. There were no differences seen between the male and female data in all brain 
regions and for both ligands. The general trend in the majority of brain regions in the 
control data set is that there is no evidence for gender bias in overall binding levels within 
the age range of the two ligands. Sex differences in normal cognitive functioning in ageing 
remain largely unexplored (Finkel et al. (2006). Studies of genetic and environmental 
contributions to sex differences in level of cognitive performance and rate of decline were 
carried out by Finkel et al. (2006). Results indicated sex differences in mean performance 
for five cognitive measures, although despite differential longevity and susceptibility to 
disease, there were no consistent indications that men and women show different patterns 
of cognitive ageing. Wahlin et al. (2006) examined how health and biological age influence 
age and sex differences in cognitive ageing. A complex pattern emerged for the mediation 
of sex differences. Although biological age accounted for sex-related variation in cognitive 
performance, health operated to suppress these differences. Overall, both health and 
biological age predicted cognitive variation independently of chronological age. Read et al. 
(2006) investigated sex differences in genetic and environmental effects on cognitive 
abilities among older adult twins. Lower performance in all cognitive measures was related 
to increasing age. A Sex x Age interaction was observed, with greater deficits in the 
performance of women compared with those of men at higher ages, however, no sex-
specific genetic influences were seen. The same genetic effects were operating for men and 
women. 
Having looked at the control group separately, the next stage was to determine whether 
there were any changes in NR2B receptor binding levels in DLB, PDD, DLBPDD and AD 
cases when compared to the age-matched controls, and to determine if there are gender 
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differences between disease groups compared to age-matched controls. This is covered in 
the following section. 
4.6.2 Disease State data (DLB, PDD, DLBPDD and AD) 
Images of DLB, PDD and AD brain sections in Figures 4.5- 4.8 show a visible difference 
between binding levels of the two ligands in each disease state, with the eH]CP-1 01,606 
levels reduced when compared with eH[Ro 25,6981, indicated by the reduced intensity of 
the image. The brain regions labelled by both ligands were similar to those labelled in the 
control sections, and again agree with published literature. The caudate, putamen, insular 
cortex, cingulate cortex and claustrum all show NR2B labelling. The difference in binding 
level between the two ligands was reflected well when statistically analysed, figures 4.10 to 
4.12 show that binding of eHJCP-101,606 in all the tissues (except the claustrum for the 
AD data) was significantly lower than with eH[Ro 25,6981 in all the disease states. This 
again would support the hypothesis that CP-1 01 ,606 labels a subtype of NR2B containing 
NMDA receptor. The data were further analysed to see ifthere were differences in the level 
ofNR2B binding between the disease states, and these data are shown in Figure 4.12(a) and 
4.12(b). Binding levels of eHJRo 25,6981 showed no significant differences between the 
disease states in any of the brain regions. This is interesting since it suggests that there is no 
significant change in NR2B receptor population in any one form of neurodegenerative 
disease compared to another. DLB, PDD and AD all have cognitive decline as a major 
symptom of the disease progression. In rodents, cognitive decline has correlated to 
decreases in NR2B subtype populations in the brain. Bai et al (2004) studied the changes in 
the expression of the NR2B subunit during ageing in macaque monkeys. They 
demonstrated that humans, non-human primates and rodents show decline in spatial 
memory abilities with increased age. They put forward that some of these decline in mice 
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are related to changes in the expression of the NR2B subunit of the NMDA receptor. More 
specifically, they showed a significant decrease in the mRNA expression of the NR2B 
subunit overall in the prefrontal cortex and in the caudate nucleus between young ( 6-12 
years) and old (24-26 years) monkeys. There were no significant changes in NR2B mRNA 
expression in the hippocampus or the parahippocampal gyrus. Previous studies in C57BL/6 
mice showed similar results to those in the prefrontal cortex, caudate and hippocampus 
during ageing, suggesting that mice could be more useful models for primates to further 
examine the age-related changes in NR2B subunit expression in several important regions 
of the brain. There is no direct quantifiable correlation between abundance of the NR2B 
subunit and severity of dementia. Previous studies by Hynd et al (2004) showed that there 
was significantly lower expression of individual NR2A and NR2B transcripts in susceptible 
regions of the AD brain, whereas expression of NR2C and NR2D transcripts did not differ 
from that in controls. Also the expression of the NRl subunit mRNA splice variants in 
Alzheimer's disease brain varied according to regional susceptibility to pathological 
damage. NMDA receptor dysfunction might give rise to the regionally selective pattern of 
neuronal loss that is characteristic of AD. Binding levels of eH]CP-101,606 between the 
disease states again showed no significant differences except in the AD data, where the 
cingulate cortex was higher than the DLB and PDD data. This result may be a reflection of 
the low n numbers, and a larger study would need to be carried out to confirm the 
significance of this finding. Table 4.13(a) showed the DLB and PDD eH]CP-101,606 
binding levels in all brain regions were less than 50% of the eH]Ro 25,6981 levels. The 
AD data showed a greater than 50% binding level compared to eHJRo 25,6981, except in 
the claustrum. It is known from Figure 4.12 however, that there is a significant difference 
between the binding levels except in the claustrum. Alzheimer's disease is characterized by 
loss of specific cell populations within selective subregions of the hippocampus. Mishizen-
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Eberz et a/ (2004) demonstrated that with increasing AD neuropathology, protein levels 
and mRNA expression for NRI and NR2B subunits were significantly reduced, while the 
NR2A subunit mRNA expression and protein levels were unchanged. Their work supports 
the hypothesis that alterations occur in the expression of specific NMDA receptor subunits 
with increasing AD pathologic severity, which is hypothesized to contribute to the 
vulnerability of these neurons. Data from Bi et a/.(2002) also suggest that alterations in 
NMDA receptor subunits, particularly NR2A and NR2B, may be important in AD, 
especially in neuronal populations that underlie impaired learning and memory. When the 
data were divided by gender, there were no trends seen between the binding of the two 
ligands. 
When the binding data for each ligand was correlated with age in each of the DLB and 
PDD disease cases, there were no significant changes occurring (with the exception of the 
DLB CP-101,606 outer insular cortex p=0.04) see figures 4.22 to 4.24. This was surprising 
at first since previous evidence points to a decrease in the NR2B subunit with age and a 
corresponding decrease in cognitive performance in animal models (Clayton et al., 2002). 
However, in the AD group, see Figure 4.25, a significant age-dependant reduction in 
eH[Ro 25,6981 binding density was evident in the striatum, nucleus accembens, cingulate 
and insular cortex. The AD cases were used to compare changes in a disease group of 
equivalent age which have dementia but do not show signs of motor complications 
associated with a reduced dopaminergic function, such as seen in PD. As previously stated, 
the DLB and PDD cases did not demonstrate this decline with age, with the exception of 
the DLB eH]CP-1 01,606 insular cortex, showing a significant decline. Possibly a wider 
age range is necessary to show any age-dependant changes in the control data, however, the 
results so far indicate age-dependant differences in the NR2B subtype populations between 
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the three dementia groups (DLB, PDD and AD) and nonnal ageing. Age is therefore a 
factor to take into consideration when carrying out further analysis. 
Having studied the effects of age on the binding levels of the two ligands, the data was then 
divided by gender to see if there were gender differences in binding across the age-range. 
Figure 4.41 and 4.42 show the male and female DLB data for eH]Ro 25,6981 and eH]CP-
101,606 respectively. In both cases there were no significant differences. This was the same 
for the DLBPDD eH]Ro 25,6981 data shown in Figure 4.43. These results provide 
evidence that the ligand binding does not vary between male and female cases, and that age 
is not an influencing factor in the binding level in either gender group across the age-range. 
However, this is not the case when analysing the AD data. There were significant age-
dependant reductions in [3H]Ro 25,6981 binding in the female caudate, putamen and 
insular cortex and male cingulate cortex. All other tissues showed a trend for decreased 
binding as age increased, although were not statistically significant. There is increasing 
evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of 
AD. The NMDA receptor antagonist memantine is used as a symptomatological and 
neuroprotective treatment for Alzheimer's disease (Danysz & Parsons 2003). Continuous 
mild activation of the receptors may lead to neuronal damage and impainnent of synaptic 
plasticity (learning). Inflammatory processes in the central nervous system are also thought 
to contribute to AD. Chronic administration of nonsteroidal anti-inflammatory drugs 
(NSAIDs) decreases the incidence of Alzheimer's disease. There are very few studies, 
however, on the cognitive impact of chronic NSAID administration. The NMDA receptor is 
implicated in learning and memory, and age-related decreases in the NMDA NR2B subunit 
correlate with memory deficits. Mesches et al (2004) administered Sulindac, an NSAID 
that is a nonselective cyclooxygenase (COX) inhibitor, to aged Fischer 344 rats for 2 
months. Sulindac, but not its non-COX active metabolite, attenuated age-related deficits in 
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learning and memory as assessed in the radial arm water maze and contextual fear 
conditioning tasks. Sulindac treatment also attenuated an age-related decrease in the NR 1 
and NR2B NMDA receptor subunits and prevented an age-related increase in the pro-
inflammatory cytokine, interleukin 1 beta (IL-l beta), in the hippocampus. These findings 
support the inflammation hypothesis of ageing and have important implications for 
potential cognitive enhancing effects of NSAIDs in the elderly (Mesches et al. 2004). 
Magnusson 1998 reported that the effects of aging on NMDA receptors may be associated 
with age-related declines in spatial learning. C57B 1/6 mice aged 3, 10, and 26 months were 
tested for spatial learning in the Morris water maze. Ten and 26 month old mice were ad 
libitum-fed or diet restricted (60% of ad libitum-fed calories). Diet restriction significantly 
improved memory performance among the 10 and 26 month olds. Diet restricted 26 month 
olds did not differ significantly from 3 month olds or any other groups. There was a 
significant correlation in memory test score with eH]glutamate binding densities for the 
NMDA receptors in the frontal cortex and CA 1 region of the hippocampus. These results 
suggest that there is a sparing of spatial memory with diet restriction in aging C57B 116 
mice. There are however several flaws in the water maze technique which must be 
considered. These include factors such as movement disorders of the animal and anxiety 
levels due to emersion in water. A human study is necessary due to these flaws making the 
water maze not an ideal model. Braak & Braak (1998) studied neuronal changes in the 
course of Alzheimer's disease. Many neuronal systems are involved in the degradation of a 
few types of nerve cells in AD. Brody (1980) reported that as the nervous system ages, an 
area-, time- and rate-specific neuronal cell loss is observed in human and animal species. 
The same data are also presented in Figure 4.47 to 4.50 showing the mean average specific 
binding data (±SD) for male and female cases for each disease state. Figure 4.47 (Ro 
25,6981 DLB) and Figure 4.50 (Ro 25,6981 AD) showed no significant differences 
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between male and female data. Figure 4.48 (CP-101,606 DLB) showed the accumbens 
binding level was higher in the female than the male, but all other regions showed no 
significant differences. Figure 4.49 (Ro 25,6981 DLBPDD) also had higher female binding 
in the caudate and putamen, with all other regions showing no differences. Apart from the 
three regions mentioned above, the overall result is that there is no gender bias with regards 
to the binding of the two NR2B-selective ligands in the regions analysed in DLB, 
DLBPDD and AD cases. There is little known about the effects of gender on the NMDA 
population in the brain, and the literature does not provide evidence for there being a bias in 
NR2B subtype binding. The data in this section would suggest that gender has very little or 
no influence on NR2B binding and therefore does not in turn influence decline in cognitive 
ability that may be associated with a decrease in NMDAR2B receptors. 
The control and disease state data so far have been analysed separately for differences in 
ligand binding levels, and age-related changes in binding as a whole data set and for male 
and female data individually. The next section looks at the disease data compared to the 
age-matched control case data to analyse for similar changes. 
4.6.3 Control v Disease State data 
The control and disease state data have been compared in Figure 4.13 to 4.19. Control 
against DLB data is shown for Ro 25,6981 and CP-101,606 binding on Figure 4.13 and 
4.14 respectively. In both cases there were no significant differences seen between the two 
groups of data in all the brain regions analysed. The only significant difference to emerge 
was a higher female binding level in DLB cingulate cortex compared to control. This may 
be due to the female control binding being lower than the male, suggesting a higher 
expression ofNR2B receptor subtype in the DLB female region compared to the others. It 
would be surprising to see an increase in NR2B receptor in the disease state compared to 
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control, since it was expected that DLB cases may have shown a decrease in NR2B 
receptor expression correspondi"g to a decline in cognitive ability and increased dementia 
compared to normal. Control versus PDD data are shown for Ro 25,6981 and CP-1 01,606 
binding in Figure 4.15 and 4.16. The binding levels for both ligands did not significantly 
vary between the two groups and the only difference in the data set was a lower Ro 25,6981 
binding level in PDD claustrum compared to control. The PDD cohort used in this study 
lacked dyskinesias since the UPDRS scores were all below 30, indicating mild movement 
disorders. The data could therefore not be related to movement correlation. Calon et a/ 
(2003) studied NMDA receptors in the brains of controls and Parkinson's disease (PD) 
patients, of which 10 of 14 developed motor complications (dyskinesias and/or wearing-oft) 
following levodopa therapy. eH] Ro 25-6981 binding to the NR11NR2B NMDA receptor 
was increased in the putamen of PD patients experiencing motor complications compared 
to those who did not (+53%) and compared to controls (+18%) whereas binding remained 
unchanged in the caudate nucleus. The results from this section showed no difference in 
PDD putamen eH]Ro 25,6981 binding levels compared with controls and a decrease in 
claustrum binding rather than an increase as described by the literature above. In human 
postmortem tissue, unchanged (Calon et al., 2003) or increased (Lange et al., 1997) NR2A 
binding and increased NR2B binding (Calon et al., 2003) has been reported. It is clear that 
the literature on NMDA receptor binding in PD in both experimental models and human 
tissue is inconclusive. The different ligands utilized to study NMDA receptor binding sites, 
extent of dopamine depletion, and severity of motor complications associated with 
dopaminergic therapy, may in part explain the differences in results between these studies. 
Another important aspect, however, is the complexity of the NMDA receptor system itself, 
and variety of different mechanisms that regulate these channels. In human postmortem 
brain, only NR1 expression has been examined closely, and in two studies was shown not 
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to be substantially altered in PD (Meoni et al., 1999 and Calon et al., 2003). NMDA 
receptors present in the striatum are crucial for dopamine-glutamate interactions. The 
abundance, structure, and function of striatal receptors are altered by the dopamine 
depletion and further modified by the pharmacological treatments used in PD (Hallet & 
Standaert, 2004). 
Figure 4.17 shows eH]Ro 25,6981 control versus DLBPDD data, with no significant 
differences seen between the two groups except when the data are divided into male and 
female. The male DLBPDD caudate and insular cortex data show a lower binding level 
than the control. This may suggest that the male DLBPDD caudate and insular cortex are 
more susceptible to NR2B receptor changes than controls. Control versus AD data are 
shown for Ro 25,6981 and CP-101,606 binding on Figure 4.18 and 4.19 respectively. There 
were no significant differences in binding level of both ligands between the two groups, 
and no gender bias was observed. Only the CP-1 01 ,606 AD cingulate cortex showed a 
significantly higher binding level than the control. The n numbers were low for the AD data 
set therefore a larger study would need to be carried out to see statistical significance 
between AD and control data. The exact cause of memory loss that leads to dementia in AD 
is not known. The amyloid precursor protein + presenilin-1 (APP+PS 1) transgenic mouse is 
a model for amyloid deposition, and like AD, the mice develop memory deficits as amyloid 
deposits accumulate. At the age when these animals developed cognitive dysfunction, they 
had reduced mRNA expression of several genes essential for L TP and memory formation 
(Arc, Zit268, NR2B, GluR1, Homer-la, Nur77/TR3). These changes appeared to be related 
to amyloid deposition, because mRNA expression was unchanged in the regions that did 
not accumulate amyloid (Dickey et al., 2003). 
The control versus disease state data were then further analysed for age-dependant changes. 
The hypothesis is that both control and disease state binding levels will decrease with age, 
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since NR2B receptor populations in the brain are thought to decrease with age and 
increasing cognitive deficits. The disease state binding levels however would be expected 
to decrease more dramatically than the normal level of decline seen in control cases. The 
NR2B subunit is implicated in neurological disease where impairment of memory may 
occur, and has been shown to decrease with age in previous studies in rodents (Clayton et 
al. 2002). 
Control versus DLB eH]Ro 25,6981 binding is shown in Figure 4.26 to 4.28. For the 
pooled male and female data and separate female data, there were no significant differences 
in binding level with increasing age in either control or DLB data sets. The male data set 
however showed a significant increase in binding in the control cingulate cortex (p=0.03), 
and decrease in binding in the control claustrum (p=0.02). Control against eH]CP-1 01,606 
binding, shown in Figure 4.29, shows no significant differences, except in the control 
insular cortex (p=0.03) and DLB outer insular cortex (p=0.04). There is border-line 
significance decrease in the control outer insular cortex (p=0.06). These results do not 
provide evidence for a clear trend in changes of the NR2B subtype populations with age in 
DLB compared with control cases. 
Control versus POD eH]Ro 25,6981 and eH]CP-101,606 data are shown in Figure 4.30 to 
4.32, and control versus DLBPDD data are shown in Figure 4.33 to 4.35. There were no 
significant differences between control and POD or control and DLBPDD binding levels in 
any of the region except those which have already been described for the eH]Ro 25,6981 
male control data above (that is, control claustrum, cingulate cortex and insular cortex) and 
the eH]CP-1 01,606 control pooled data insular cortex also already described. The main 
finding in this section is again relating to the AD data. Figure 4.36 to 4.38 shows the 
control and AD binding levels against age for both ligands. The eH]Ro 25,6981 control 
pooled male and female data is as previously described, however the AD data shows 
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significant age-dependant decreases in binding for all brain regions with the exception of 
the claustrum and internal and external globus pallidus. The separate female data set also 
shows significant decreases in binding with age in all brain areas except the claustrum, 
outer insular cortex and cingulate cortex. The findings from this study of AD cases show 
that with increasing age, the population of NR2B-containing NMDA receptors is 
decreasing. These data support studies which have been outlined previously in this section. 
An interesting observation however, is that the binding levels in AD cases at the early ages 
studied, showed higher binding levels than the age-matched control cases, which with 
increasing age, dropped to levels similar to those seen in the age-matched controls. This 
data would suggest that elevated NR2B levels might be an early marker for a predisposition 
for AD progression later in life. 
Haug & Eggers (1991) studied ageing of the human cortex cerebri and corpus striatum. 
They found that there was not a loss of the neurones themselves with age, but the size of 
the neurons and the number ofsynapses decrease with age. Various regions ofthe brain age 
differently and there is a genetically determined decreased brain function during ageing 
which can only be inhibited, not permanently preserved. Perhaps there is a decrease in 
NR2B receptor subtype with age as the size rather than abundance of NR2B expressing 
neurons decreases with age. Huttenlocher ( 1979) studied developmental changes and 
effects of normal human ageing (ranging from newborn to 90 years) by focusing on 
synaptic density in the human frontal cortex. The human cerebral cortex showed a loss of 
neurons and synapses at late developmental stage. 
The next section focuses on the disease state symptom and cognitive ability data collated 
from clinical records of the cases used in this study. 
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4.6.4 Disease State Symptom Correlation Studies 
In this section the eH]Ro 25,6981 and eH]CP-1 01 ,606 binding levels have been correlated 
with scores from various clinical tests carried out at the last examination before death of 
each subject in the study. Figure 4.51, 4.51(a) and 4.52 show the eH]Ro 25,6981 specific 
binding levels against MMSE (see section 4.3) and MTS (see section 4.3.1) scores. For all 
the pooled DLB, POD, DLBPDD (Lewy Body dementias) and AD cases and in all the 
brain regions analysed there were no significant changes in binding level with increasing 
score. Only the Lewy Body dementias insular cortex showed a border-line decrease in 
binding with increasing MMSE score. There was however an overall trend for binding 
levels to decrease as MMSE and most notably MTS score increased in all the regions 
analysed. An MMSE score of ::;23/30 and an MTS score of $.30/37 indicates cognitive 
impairment. The data would suggest an increase in binding with a decrease in score and a 
parallel decrease in cognitive performance. This does not support the theory that the NR2B 
subtype of NMDA receptor may decrease with age and cognitive decline. Sze et al (200 1) 
report that phosphorylated NR2B (56%, P<0.01) were selectively reduced in entorhinal 
cortex in AD when compared to controls, and that both phosphorylated and non-
phosphorylated NMDA receptor protein levels in entorhinal cortex correlated (increased as 
score increased)with Mini-Mental Status Examination (MMSE) and Blessed (BIMC) scores. 
MMSE scores in this study ranged from 13-30, indicating all cases studied had cognitive 
impairment within a similar range to the present study. Analysis of all cases, showed the 
levels of P-NR2B and NR2B in entorhinal cortex correlated with MMSE scores (r=0.675, 
P<0.005; r=0.620, P<0.01) and Blessed (BIMC) scores (r=-0.655, P<0.005; r=-0.556, 
P<0.025. The loss ofNRl protein correlated with the severity of cognitive impairment, as 
measured by the MMSE, BIMC (Blessed Information, Memory and Concentration Test), 
and Free Recall (memory recall test) scores (r=0.692, P<0.01; r=-0.641, P<0.01; r=0.586, 
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P<0.025) in the hippocampus. NR2B protein levels in the hippocampus correlated with 
MMSE and BIMC scores (r=0.588, P<0.025; r=0.565, P<0.025). The binding data versus 
UPDRS score (see section 4.4) are shown in Figure 4.53 and 4.54 for DLB, DLBPDD, 
PDD and AD respectively. Figure 4.53 shows no correlation between binding level and 
UPDRS score in any of the brain regions. This suggests that the severity of PD symptoms 
experienced by the patient does not affect the expression of NR2B receptors in the brain 
regions studied here, or vice-versa. The most significant and interesting observation from 
all the symptom studies in this section is shown in Figure 4.54. Here the binding level 
against UPDRS score for AD cases is shown. There is a significant decrease in binding 
with increasing score in the caudate and putamen, as well as border-line significant 
decreases in binding in the insular cortex, cingulate cortex and outer insular cortex. Studies 
show that a continuous mild activation of NMDA receptors may lead to neuronal damage 
and impairment of synaptic plasticity and learning (Danysz & Parsons, 2003). These results 
show that as UPDRS score increases, showing behavioural and motor deficits, NR2B 
receptor populations are decreasing, shown by decreases in binding level. Conversely, and 
in support of this data, Tang et a/ (1999) reported that transgenic mice over-expressing the 
NR2B subunit exhibit superior ability in learning and memory in various behavioural tasks, 
showing that NR2B is critical in gating the age-dependent threshold for plasticity and 
memory formation. The disease cases in this study had low motor impairment, with 
UPDRS scores less than 30, indicating mild movement deficits in the cohort. Therefore 
expression ofNR2B may not be affected significantly by this factor. The changes in NR2B 
expression seen in the AD cases may be due to the behavioural side of the UPDRS 
assessment rather than the cognitive, even though UPDRS score is low. 
The scoring system for each of the depression, delusion, dementia and visual hallucination 
data is the same, ranging from 0-2, where the severity of the symptoms experienced were 
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given a score of either 0 = none, 1 = mild and 2 = severe. The data for these are shown in 
Figure 4.55 to 4.62. There were no significant differences between eH]Ro 25,6981 binding 
levels between any of the scores, and in any of the brain regions analysed, this applied to 
both DLB and AD data alike. The only significant difference seen was in the DLB outer 
insular cortex visual hallucination data, where the binding for score 1 was higher than score 
0. The data does not provide evidence for a change in NR2B binding with an increase in 
severity of psychiatric symptoms. The previous literature suggests a decline in NR2B 
receptor subtype with increasing age (Bai et al. 2004) which may be associated with 
decline in cognitive function, although the dementia results from this study do not show a 
significant change in binding with increasing severity of the symptoms. The dementia score 
defines a qualitative analysis and cannot be considered to be accurate as the MMSE and 
MTS data which is quantitative. Mesches et al (2004) used Sulindac and showed improved 
memory and increased NMDA receptor subunits in aged Fischer 344 rats. The results from 
this study do not however appear to suggest that a decreased ability in learning and memory 
(represented by increased severity of symptom) shows a decrease in NMDARB receptor 
subunits. The psychotic symptom data in the study, that is, the delusion and visual 
hallucination data, did not show any significant differences between binding levels and 
score with the exception in the DLB outer insular cortex visual hallucination data. Several 
lines of investigation support a hypothesis of glutamatergic dysfunction in schizophrenia, 
including reports of altered NMDA receptor subunit and associated intracellular protein 
transcripts in the thalamus of elderly patients with schizophrenia (Clinton & Meador-
Woodruff, 2004). 
Akbarian et al. (1996) reported no significant changes in the expression of NR2A, NR2B, 
NR2C, or NR2D mRNA in prefrontal, parieto-temporal, and cerebellar cortices of 
postmortem brains from schizophrenic patients compared with control subjects. However, 
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using different methodology, Grimwood et al. (1999) found somewhat conflicting results. 
As measured by radioligand binding with eH]ifenprodil, NR2B-containing receptors are 
selectively up-regulated in the superior temporal cortex in schizophrenia, but not in the pre-
motor cortex. Although changes in transcript levels are not always indicative of 
corresponding alterations in protein expression (and visa versa), these findings suggested 
that further investigation of the role ofNR2B in schizophrenia is needed. Gao et al. (2000) 
analyzed postmortem hippocampal tissue from people with schizophrenia and from control 
subjects. Glutamate receptor autoradiography of various subfields in the hippocampus 
provided no evidence of ligand-binding differences between the groups. Interestingly, in 
situ hybridization experiments were also performed and the level of mRNA for the NR2B 
subunit in CA2 of the hippocampus was found to be 40% higher in schizophrenia tissue 
than in control tissue. 
4.6.5 Overall Summary. 
Some key findings have come out of the work done in this chapter. The first observation is 
the general overall preservation of NR2B-containing receptors in the control and disease 
state cases over age. Published literature states that NMDA receptors are involved in 
memory, learning and synaptic plasticity (Loftis & Janowsky, 2003; Tang et al, 1999) and 
that with advancing age there is a decrease in the expression of the NR2B subunit in 
rodents (Clayton et al 2001; Bi et al2002; Hynd et a/2004; Mishizen-Eberz et al 2004). 
This decline could be associated with a decline in cognitive ability, both in normal ageing 
and with pathological progression. The data from this study shows that in general there is 
no decline in NR2B-containing receptor expression with age in the human cases studied, 
and therefore does not fully agree with the previous published rodent data. This means that 
functional NR2B receptors are still present in several brain regions of normal and disease 
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state aged cases. Functional receptors are therefore available as therapeutic targets for 
NMDA antagonist compounds, which could potentially be used to alleviate symptoms of 
cognitive decline associated with AD, DLB and PD as seen in the cases used in this study. 
High levels of NR2B expression were seen in the earlier age cases of AD. NR2B levels 
were higher than those seen in the control and other disease state cases in that age range, 
and showed a marked decline with increasing age. The decrease however brought the level 
of NR2B expression down to similar levels seen in the other cohorts and did not decrease 
beyond the other older age range levels. The higher NR2B expression seen in the AD cases 
could act as an early marker for the disease, showing an alteration in NR2B expression to 
be indicative of later AD progression. There is a limited correlation overall of NR2B 
expression to dementia and psychiatric scores in the tissues studied. A general trend for 
increased binding levels with decreasing MMSE and MTS score was seen in the Lewy 
Body and AD cases. The AD cases also showed a general increased binding level with 
decreasing UPDRS score. The psychotic symptom data in the study (delusion and visual 
hallucination data) did not show any significant differences between binding levels and 
score with the exception of the DLB outer insular cortex visual hallucination data. In 
selective brain regions of those studied, there were some gender differences seen in the 
control cohort. The control male cingulate cortex binding level significantly increased with 
age (p=0.03), and the control male claustrum binding level significantly decreased with age 
(p=0.02). 
This study clearly demonstrates that CP-101,606 and Ro 25,6981 label distinct NMDA 
NR2B sub-type populations in the human brain, and that NR2B expression does not 
significantly decrease with age in the control and disease state cases used. Additional 
experiments are required to assess any further NR2B expression alterations that may exist 
in a wider age rm1ge than used here, Wld using a larger cohort. 
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Chapter 5 
Overall discussion and future direction 
The overall aim of this project was to carry out a comparative study of rodent and 
human brain in ageing and disease using novel NMDAR-2B selective probes. The 
rodent brain study covered the age range from postnatal day 21 (3 weeks) to adult 
(3 months). The human study covered control and pathological (DLB, PDD and 
AD) cases, across the age range 62 to 92 years. The study involved a variety of 
experimental techniques to analyse the abundance, distribution and temporal 
changes of both the NR2B subunit protein and NR2B containing receptor 
complexes. These included ligand autoradiography, radioligand binding and 
immunohistochemistry. 
Previous studies have revealed the subtype selectivities and affinities of Ro 
25,6981 and CP-101,606 for binding to recombinant mouse NR2B receptors as 
well as native NR2B rodent receptors (Chazot et al. 2002b; Menniti et al. 1997: 
Mutel et al, 1998). Previous evidence from the laboratory suggested that Ro 
25,6981 and CP-101,606 label distinct populations of mouse NR2B-containing 
receptors (Chazot et al. 2002b). Therefore, the first part of this study involved 
ligand autoradiography of the adult mouse brain. eHJRo 25,6981 and eHJCP-
101,606 NR2B-selective ligands were used to map the distribution pattern of 
NR2B NMDA receptors and the difference between the binding levels of the two 
ligands in mouse brain sections. Both Ro 25,6981 and CP-101,606 showed high 
binding levels in the CA1, CA3 hippocampal subflelds, granule layer of the 
dentate gyrus, entorhinal cortex and outer layers of the frontal cortex, with the 
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lowest binding levels seen in the thalamus, inner layers of the frontal cortex, 
pyramidal cell layer of the hippocampus and cerebellum. There were significantly 
higher levels of eHJRo 25,6981 binding in all the regions analysed, with the 
exception of the pyramidal cells, the frontal cortex inner layer and the cerebellum. 
The NR2B distribution and abundance shown by these results supports the 
published literature and provides further evidence for two distinct classes of 
NMDA-R2B antagonists, represented by Ro 25,6981 (all NR2B receptors) and 
CP-101,606 (NR1/NR2B subtype only) (Chazot et al. 2002b). 
A HEK 293 clonal cell model system was employed to analyse the inhibition of 
eHJCP-101,606 binding by Ro 25,6981 to NR1/NR2B receptors. Transfection of 
HEK 293 cells have been successfully used in previous studies, and were 
therefore chosen for this study (Chazot et al, 1999). Radioligand binding studies 
revealed displacement of eHJCP-101,606 binding by Ro 25,6981, which 
demonstrates that CP-101,606 and Ro 25, 6981 can bind to overlapping binding 
sites on the NMDA receptor. 
The main focus of this thesis was to study the native NR2B subtype receptor 
population in the rodent and human brain in two stages of ageing. 
Pharmacological characterisation of NR2B ligands binding to native receptors in 
3-week old and adult 3-month rat forebrain membranes was performed using 
eHJRo 25,6981 and eHJMK.-801. Firstly, the stimulation of eHJMK.-801 by 
spermidine and histamine (NR2B positive modulators) was more pronounced in 
the P21 rat brain than the adult. This is consistent with the hypothesis that the 
level of NR2B expression is higher in P21 than the adult rat brain (Dumas 2005). 
The saturation binding data for eH]Ro 25,6981 binding shows that there were 3-
fold higher levels of NR2B-containing receptors in the P21 rat brain than the 
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adult, although the affinities were very similar, with Ko values at 9.5 and 11.9nM, 
respectively. The inhibition of eH]Ro 25,6981 binding by ifenprodil, haloperidol, 
Ro 25,6981 and CP-101,606 was analysed and revealed that each ligand bound to 
variable percentages of high- and low-affinity binding sites in P21 and adult rat 
forebrain membranes. The results provide further evidence for heterogeneity in 
NR2B subunit containing receptors, and that the composition of the receptor can 
affect the pharmacological properties, shown here by the differences in binding 
between the NR2B-selective ligands. 
Having studied the pharmacological properties of the native NR2B-containing 
receptors in the rat brain membranes, the distribution pattern and abundance of 
these receptors was further studied in the rat brain for both P21 and adult age 
groups, using ligand autoradiography. Firstly, there were higher levels of eH]Ro 
25,6981 binding in P21 rat brain tissue than in adult tissue, confirming again a 
higher expression of NR2B-containing NMDA receptors in the P21 tissue. The 
exceptions to this were seen in the CA3 SO, thalamus and striatum where binding 
levels were very similar between the two ages. In contrast, there were similar 
binding levels of [3H]CP-101,606 in the P21 and adult rat brain sections with the 
exceptions being the CA 1, outer regions of the frontal cortex and the striatum, 
which showed significantly higher binding levels of eH]CP-101,606 in the adult 
than in the P21 tissue. Therefore, these data show that Ro 25,6981 binding 
decreases with age, and CP-101,606 binding remains constant or in certain areas 
increases. No significant differences in binding levels of the two ligands were 
seen in the adult tissue, and interestingly, higher binding levels of Ro 25,6981 
than CP-101, 606 were seen in the P21 tissue. Therefore, if the NR1/NR2B 
subunit subpopulation remains constant or is increasing with age (suggested by 
the CP-1 01 ,606 results) yet the overall NR2B-containing receptor population is 
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decreasing with age (suggested by the Ro 25,6981 results), then perhaps another 
NR2 subunit population is decreasing in compensation. This further supports the 
theory that these two ligands are labelling distinct populations of NR2B receptors. 
Furthermore, there is an age-dependant decline in overall NR2B subtypes between 
3 weeks and 3 months of age in rats. Clear evidence for a switch in NR2B 
subtypes during the earlier period of ageing is presented in this thesis. 
A preliminary immunohistochemical study was carried out using in-house 
produced and purified anti-NR2B receptor antibodies (Chazot et al, 1992). These 
were used as immunological probes to study the cellular distribution and 
abundance of native NR2B subunit protein in P21 and adult rat brain. This study 
builds on previous results using NMDAR subunit-specific antibodies in the rat 
brain (Thompson et al, 2002). Results showed that there was a greater expression 
of NR2B protein in the P21 rat brain than the adult, which agrees with the 
autoradiography results from this project. The main areas of NR2B expression 
labelling were the outer layers of the frontal and entorhinal cortex, thalamus, 
striatum and stratum oriens and radiatum of the CA1, CA2 and dentate gyrus of 
the hippocampal formation, again consistent with the ligand autoradiographical 
data. 
Future studies to analyse rodent brain sections from a wider age range would build 
on existing data that suggest plastic changes in early adulthood. For instance, 
analysis of rodent brain from birth to 12 months in set time increments, would 
give a detailed overview of exactly how the expression of NR2B receptors are 
altering at each stage of development. This earlier period of· ageing covers 
changes in NR2B expression possibly related to changes in synaptic plasticity and 
development. 
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The second part of this thesis investigated the NR2B receptor in the human brain, 
in both control and a range of common dementia cases over late adulthood (age 
62-92). The NMDA receptor is implicated in normal neuronal development, 
normal ageing and neurological diseases where changes in learning and memory 
may occur (Piggott et al., 1994). Autoradiographical studies using eH]Ro 25,6981 
and [3H]CP-101,606 showed that NR2B-containing receptors where present in the 
striatum, claustrum, insular cortex, cingulate cortex, and internal and external 
globus pallidus. Contrary to our initial prediction, this study revealed a general 
overall preservation of NR2B-containing receptors in the control and disease state 
cases over age, which is distinct from the published rodent literature (Magnusson, 
2000; Tamaru et al, 1991; Wenk et al, 1991; Kito et al, 1990) where a decline in 
NR2B expression with age, corresponding to a decline in cognitive ability with 
age has been reported. This indicates that there are functional NR2B-containing 
receptors present in various brain regions of normal and disease state aged cases, 
which could be used as therapeutic targets, to manage some of the symptoms 
associated with neurological degeneration. The study demonstrated that Ro 
25,6981 and CP-101,606 label distinct NMDA NR2B subtype populations in the 
human brain (as seen in the mouse and rat), and that there is no significant 
decrease in NR2B receptor expression with age (in contrast to the rodent reports) 
in control, DLB and PDD cases used in this study. Interestingly, higher levels of 
NR1/NR2B containing receptors were seen in the earlier age cases of AD when 
compared to controls and other disease state cases. The reduction in binding levels 
with age however, reached similar levels seen in the other cohorts and did not 
decrease beyond the controls. The higher NR2B expression seen in the younger 
AD cases may act as an early marker for the disease, indicating that an alteration 
in NR2B expression to be indicative of later AD progression. The study also 
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showed a modest limited correlation between NR2B expression and dementia and 
psychiatric test scores, where binding level increased as scores decreased, 
indicating a higher NR2B expression correlating to less severe cognitive decline. 
In selective brain regions, there were some gender differences seen in the control 
cohort. The control male cingulate cortex binding level significantly increased 
with age (p=0.03), and the control male claustrum binding level significantly 
decreased with age (p=0.02). Notably, NR2B-containing receptors are 
significantly lower in control female cases than male counterparts, and all DLB 
cases. Further studies to assess the effects of age on NR2B receptor expression 
over a wider age range in control and disease state cases will prove extremely 
useful, in order to reveal if the trends seen in this data set are indeed a general 
principle. A larger cohort of control as well as disease state cases, especially those 
labelled with eHJCP-101,606 would provide a statistically larger and therefore 
more complete data set. Further research will involve autoradiographical analysis 
of PD cases, which can be compared to the present data for differences in receptor 
expression and dyskinesia symptom correlation. The overall preservation of 
NR2B receptors with increasing age opens up the possibility for potential changes 
in other NMDAR subtype populations. Other receptor subtypes may show an 
alteration in expression over age, and further autoradiographical studies would 
provide this information, painting a clearer picture of the changes which are 
occurring in the composition of the NMDA receptor, not only in normal ageing, 
but in the progression of pathological conditions. 
In summary, the main findings from this research project were: 
I. Reduction and changes in the overall NR2B subtype populations between 3 
week-old and adult rat brain. 
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2. Ro 25,6981 and CP-101,606label distinct NMDA NR2B subtype populations 
in the human brain (as seen in the mouse and rat), demonstrating that distinct 
ifenprodil-like compounds distinguish between NR2B subtype populations. 
3. NR2B subtype preservation in human ageing and major human dementias, 
and limited correlation to MMSE scores in human dementias. 
4. First evidence that the NR2B subtype plays no or only a limited role in 
neuronal loss and learning deficits in human dementias 
This present study builds on the work from previous experiments which have 
provided a wealth of information. The research has enabled a greater 
understanding of the pharmacology of a variety of NR2B-selective ligands, and 
has shown clearly distinct binding properties of the Ro 25,6981 and CP-101,606 
NR2B antagonists. The rodent brain analysis has confirmed previous findings in 
terms of brain regions showing NR2B expression, but has also provided further 
data on NR2B subtype population changes occurring during the early adult 
developmental period. This project presents the first data on the distribution and 
abundance of NR2B-containing receptors, labelled by Ro 25,6981 and CP-
1 01 ,606, in aged human control and disease cases, and increases understanding 
not only of NMDAR changes occurring with normal ageing, but also those 
occurring in pathological states over age. This work in turn has provided a 
platform from which many future studies will arise, since there are many 
unanswered questions about the pharmacological properties of native NMDA 
receptors, and their composite alterations in a variety of developmental and 
pathological stages. 
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Appendix One: Chapter 3, Section 3.2.4 Continuation. 
Additionallmmunohistochemitsry data using an in-house generated anti-NR2D 
antibody. The anti-NR2D antibodies were generated and characterised as described 
by Thompson et a/ (2002). The peptide corresponding to the amino acids 1307-1323 
(LGTRRGSAHFSSLESEV) of the mouse NR2D subunit was conjugated to 
thyroglobulin by the glutaraldehyde method. The resultant conjugate was used to 
generate polyclonal antibodies in rabbits. See Chapter 3, section 3.2.4 for methods. 
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20 P21 CA2 
2DP21 CA3 
Figure 1 Immunohistochemical staining of P21 rat Hippocampal 
Formation using DAB against anti-NR2D antibody. 371 
2DAdultCAl 
2D AdultCA2 
2D AdultCA3 
Figure 2 Immunohistochemical staining of Adult rat Hippocampal 
Formation using DAB against anti-NR2D antibody. 
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xlO 
Figure 3 Immunohistochemical staining of P21 and Adult rat 
Thalamus and Striatum using DAB against anti-NR2D antibody. 
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Figure 4 Immunohistochemical staining of P21 and Adult rat Frontal 
and Entorhinal Cortex using DAB against anti-NR2D antibody. 
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\ PROBING THE NR2B IN THE MAMMALIAN CENTRAL NERVOUS SYSTEM: FURTHER EVIDENCE 
FOR DISTINCT NR2B LIGANDS. 
R.L. Sheahan1, M. Lake1•2, M. Piggotr, and P.L. Chazot1 
1School of Biological and Biomedical Sciences, Durham University, Durham, UK; 2MRC Unit, Newcastle 
General Hospital, Newcastle-upon-Tyne, UK 
The N-methyl-D-aspartate (NMDA) receptor is a heteromeric ligand-gated ion channel comprising a range of 
subunits, namely NR1, NR2A-D and NR3A-B. The specific expression profile of the NR2B subunit in the 
brain, is developmentally and regionally regulated, and is involved in key processes such as learning, memory 
and motor coordination. There is clear evidence for different types of NR2B-containing receptors (NRl/28, 
NR1/2B/2A, NR1/2B/2D) (Chazot, 2004). Previous studies in our laboratory have provided evidence that 
there are at least two classes ofNR2B-selective compounds, one class which binds all NR1/NR2B-containing 
receptors (Ro 25,6981) and one which binds to just the dimeric NRI/NR2B receptor subtype (CP-101,606) 
(Chazot et al., 2002). The aims of this study are to map the distinct NR1/NR2B-containing subtypes and in 
the murine and human brain using ligand autoradiography (Mute) et al, 1998). 
Both [3H] Ro 25,6981 and[~ CP-101,606 specifically labelled mouse and human hippocampus, thalamus, 
striatum and cortex, consistent with our previous immunohistochemical studies (Thompson et al., 2002). 
Notably, the number of specific eHJ Ro 25,6981 binding sites were consistently higher than fH] CP-101,606 
binding sites in both murine (not shown) and human brain structures (n = 16-26, p <0.0001) (Figure 1). These 
data provide further evidence that CP-101,606labels a subset ofNR2B-containing receptors. 
Figure 1 Control human brain 
Ligand autoradiography (mean 
± SD for 16-26 samples) 
~H]Ro-25,6981 
lllllllllcaudate nucleus 
11111111 putamen 
E3 insular cortex 
UJD claustrum 
c:;;n nucleus accumbens 
~limbic cortex 
Competition binding studies were used to determine the pharmacological properties of another NR2B ligand, 
ifenprodil using [3H] Ro 25,6981 binding to adult or P21 male Sprague-Dawley rat forebrain membranes. 
The assay was performed as described in Chazot et al., 2002, except non-specific binding was defined by 100 
~M Ifenprodil. The competiton curve for ifenprodil binding, using P21 membranes, displayed a pseudo Hill 
slope coefficient close to unity (nH = -0.87 ± 0.20), with an IC50 value of 8.69 ± 1.32~M. In contrast, the 
curve for ifenprodil binding using adult membranes was best fitted to a two-site fit model, with the nH = 0.65 
± 0.23 (high affinity site, ECso = 0.25~M, 35 ± 5%; low affinity site, EC50 = 10.1 ~M, 63 ± 5%). Therefore, 
we provide preliminary evidence that ifenprodil binds to more than one subtype of NR2B-containing 
receptors present in the adult forebrain, and that distinct populations of NR2B-containing receptors exist in 
young and mature rat forebrain. 
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